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unchecked	 cell	 growth.	 	 Cells	 typically	 progress	 gradually	 through	 a	 series	 of	 steps,	 from	
hyperplasia,	to	dysplasia,	to	neoplasia,	and	sometimes	malignancy,	usually	driven	by	genetic	
changes,	 that	 disrupt	 core	 processes	 that	 normally	 help	 regulate	 cell	 growth.	 	 These	
processes	 have	 been	 categorized	 into	 ten	 distinct	 functions,	 known	 as	 “the	 Hallmarks	 of	
Cancer.”		Initially,	Hanahan	and	Weinberg	postulated	that	cancer	cells	might	have	additional	
capabilities	 across	 six	 different	 categories:	 sustained	 growth	 signaling,	 evasion	 of	 growth	





Figure	1:	Hallmarks	of	Cancer.	 	Original	 six	 canonical	ways	 that	 cancer	 cells	have	added	
abilities	(2).		Used	with	permission:	Hanahan,	D.,	and	R.	A.	Weinberg.	2011.	Hallmarks	of	
cancer:	the	next	generation.	Cell	144:	646-674.	L/N	4294491470430.	
Subsequent	 research	 has	 strongly	 indicated	 two	 other	 hallmarks:	 deregulating	 cellular	






Hanahan,	 D.,	 and	 R.	 A.	Weinberg.	 2011.	 Hallmarks	 of	 cancer:	 the	 next	 generation.	Cell	
144:	646-674.	L/N	4294491470430.	
These	 ideas	 provide	 a	 framework	 for	 understanding	 how	 tumors	might	 arise,	 and	 how	
they	differ	from	normal	cells.	
The	changes	necessary	 for	 tumorigenesis	 can	be	acquired	 in	a	 variety	of	ways.	 	 In	
cancer	 predisposition	 syndromes,	 germline	mutations	 can	 be	 inherited	 from	 the	 parents.	
Alternatively,	changes	in	the	genome	can	be	acquired	somatically,	either	from	errors	during	
cell	division,	or	from	exposure	to	environmental	mutagens	such	as	smoking	or	UV	rays.		For	





no	 functional	 impact.	 	 Distinguishing	 cancer-causing	 driver	 mutations	 from	 passenger	
events	remains	a	key	challenge	in	understanding	cancer	etiology	(4).	
Beyond	 just	 looking	 for	 genetic	 changes	 in	 the	 genome,	we	 increasingly	 find	 that	
changes	in	the	transcriptome	and	epigenome	can	also	lead	to	disease,	including	cancer	(5-
7).	 	Moreover,	 this	makes	 integrative	 approaches	 that	 seek	 to	 completely	 profile	 tumors	
across	 the	 genome,	 transcriptome,	 and	 epigenome	 uniquely	 powerful	 to	 quantify,	 and	
evaluate	as	many	changes	as	possible	(7).	For	example,	pairing	whole	genome	sequencing	





Sarcomas	 are	 a	 relatively	 rare	 mesenchymal	 cancer,	 making	 up	 ~1%	 of	 all	 adult	
tumors	and	15%	of	all	childhood	tumors	(9-11).	They	are	most	often	found	in	the	arms	or	
legs	 (60%),	 and	 chest	 or	 abdomen	 (30%),	 but	 they	 can	 be	 either	 soft	 tissue	 or	 bone	
depending	on	the	location	(11).	
The	large	majority	of	soft	tissue	and	bone	sarcomas	do	not	have	a	known	causative	
factor.	 	 There	are	 some	 isolated	 reports	 that	 suggest	 that	 soft	 tissue	 sarcomas	may	arise	









in	 the	 past	 30	 years	 (12).	 The	 primary	 options	 for	 treatment	 are	 surgery,	 radiation,	
chemotherapy,	 and	 targeted	 therapy.	 	 Surgery	 remains	 the	 most	 commonly	 accepted	
therapeutic	 option,	 but	 requires	 removal	 of	 healthy	 tissue	 with	margins	 as	 wide	 a	 1	 cm	
because	 even	 microscopically	 small	 portions	 have	 been	 associated	 with	 recurrence,	
metastasis	and	death	(11).	Under	ideal	conditions	with	low	grade	sarcomas,	and	removal	of	
all	 tumorigenic	 tissue,	 local	 control	 is	 about	 93%	 (9).	 Clinicians	 are	 still	 searching	 for	 a	
consensus	 as	 to	 the	 best	 chemotherapy	 and	 radiotherapy	 options	 (11),	 raising	 the	
possibility	 that	 better	 molecular	 profiling	 to	 inform	 treatment	 options	 could	 improve	
patient	outcomes.		
Without	 treatment,	 sarcomas	 are	 highly	 likely	 to	 metastasize	 and	 are	 considered	
highly	 aggressive,	 accounting	 for	 a	 disproportionate	 share	 of	 mortality	 in	 young	 adults.	
(SEER	 Cancer	 Statistics	 Review	 1975-2008;	
http://www.seer.cancer.gov/csr/1975_2008/)(11,	 13).	 	 In	 fact,	 the	mean	 age	 of	 onset	 for	
sarcomas,	 in	 part	 due	 to	 hereditary	 syndromes,	 is	 earlier	 than	 for	 many	 other	 types	 of	
cancer	(14).	Therefore,	identification	of	sarcoma-related	genes,	either	germline	variants,	or	
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acquired	 somatic	 variants,	 is	 considered	 vitally	 important	 for	 diagnostic	 testing	 to	 help	






(11).	 	 Because	 sarcomas	 are	 both	 rarer	 tumor	 types,	 and	 because	 they	 comprise	 such	 a	
heterogeneous	 grouping	 of	 tumors,	 it	 is	 challenging	 to	 isolate	 enough	 tumors	 of	 similar	
subtyping	 to	 generate	 sufficient	 statistical	 power	 to	 identify	 drivers,	 often	 requiring	
extensive	collaborations.	 	Moreover,	 these	data	are	 further	complicated	because	not	only	
are	sarcomas	very	diverse	(numerous	subtypes),	but	also	each	sarcoma	is	heterogeneous	in	
composition.		Sarcomas	are	frequently	composed	of	bone,	cartilage,	and	fat	(13),	which	may	
further	 obfuscate	 and	 hinder	 identification	 of	 important	 genes	 for	 tumorigenesis,	
particularly	if	a	driver	gene	need	only	be	present	in	one	of	these	tissues.	
Two	prominent	papers	were	 recently	published	on	soft	 tissue	sarcomas	 (STS).	 In	a	
Cell	 paper,	 out	 of	 the	 Cancer	 Genome	 Atlas	 network	 (TCGA),	 the	 authors	 sequenced	 six	
types	 of	 soft	 tissue	 sarcomas,	 the	 majority	 of	 which	 are	 leiomyosarcomas	 (LMS)	 and	
liposarcomas	(LPS)	(10).	LMS	were	again	a	focus	in	the	second	paper,	from	Chudasma	et	al.	
and	 published	 in	Nature	 Communications	 (15).	 Both	 studies	 found	 that	 adult	 STSs	 have	
heterogeneous	 mutational	 profiles	 with	 copy	 number	 aberrations	 (CNA)	 consistent	 with	
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(e.g.	CNAs	and	point	mutations),	 to	 changes	 in	 the	 transcriptome,	methlyome,	or	protein	
levels.		For	example,	most	LMS	have	elevated	signaling	in	PI3K/AKT	signaling,	and	over	70%	
have	 at	 least	 shallow	 deletions	 in	 TP53,	 RB1,	 and	PTEN.	 	 The	majority	 of	 LMS	 also	 have	
elevated	miR-143,	and	miR-145.		However,	two	subtypes	of	LMS,	gynecologic	LMS	(ULMS),	
and	 soft-tissue	 LMS	 (STLMS)	 have	 distinct	 differences	 in	 the	 methylome	 and	 in	 reverse	
phase	protein	array	(RPPA)	analyses.	ULMS	showed	hypomethylation	of	ESR1	target	genes,	
something	 not	 seen	 in	 STLMS.	 	 RPPA	 showed	 that	 the	 DNA	 damage	 pathway	 was	more	
active	 in	ULMS	over	 STLMS,	 but	 that	 the	HIF1	 inflammation	 pathway	was	more	 active	 in	
STLMS	over	ULMS	(10).			
Taken	together,	these	data	implicate	CNAs	as	a	key	player	in	both	LMS	and	LPS,	and	
indicate	 sarcoma	 subtypes	 have	 distinct	 molecular	 profiles,	 which	may	 drive	 therapeutic	
approaches	for	clinicians	 in	the	future.	 	Ultimately,	 the	data	suggest	that	all	sarcomas	are	
not	 likely	 to	 share	 the	 same	 etiology	 and	 that	 sequencing	 of	 similar	 sarcomas	 may	 be	
necessary	to	avoid	confounding	from	multiple	types	of	sarcomas.	
However,	the	authors	do	note	a	role	for	point	mutations	in	soft	tissues	sarcomas.		In	
addition	 to	 CNAs	 frequently	 occurring	 somatically	 in	 the	 MDM2-p53	 and	 p16-CDK4-RB1	
pathways,	the	most	recurrently	mutated	genes	across	sarcoma	types	in	both	studies	were	a	
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on	 acquired	 somatic	 changes.	 A	 third,	 slightly	 older	 study,	 by	 Ballinger	 et	 al.	 looked	 at	
germline	genetic	risk	factors	for	sarcomas	(16).		These	included	a	mix	of	both	sporadic	and	
familial	sarcomas,	across	a	broad	spectrum	of	sarcoma	types,	including	soft	tissue	and	bone	
sarcomas,	 with	 publically	 available	 Caucasian	 data	 used	 as	 controls	 to	 eliminate	
polymorphic	 alleles	 from	 consideration.	 	 Using	 targeted	 exon	 sequencing	 of	 72	 genes,	
selected	for	known	impact	 in	cancer,	Ballinger	et	al.	found	that	risk	generally	fell	 into	two	
groups:	classic	monogenic	variation	(~80%),	such	as	p53	(1%	of	all	sarcomas),	and	polygenic	
rare	 variation	 (~20%).	 	 Individuals	 classified	 as	 having	 polygenic	 rare	 variation	 had	





repair;	 the	authors	 argue	 that	 it	 should	now	be	 considered	a	 sarcoma	 susceptibility	 gene	
(16).	Ultimately,	more	 than	half	 of	 the	 patients	 had	 variants	 predicted	 to	 be	 deleterious,	








arrest	 and	 apoptosis.	 Moreover,	 germline	 mutations	 and	 deletions	 in	 p53	 lead	 to	 Li-
Fraumeni	Syndrome	(LFS),	a	rare	cancer	predisposition	syndrome	that	has	a	high	incidence	
of	sarcomas,	suggesting	that	p53	may	play	a	role	 in	sarcomagenesis	 (20,	21).	 	Probably	 in	
part	 due	 to	 LFS,	 it	 is	 considered	 to	 be	 the	 strongest	monogenic	 driver	 of	 sarcomas	 (16).	
Conversely,	based	on	publicly	available	data	 from	cBio,	p53	alterations	are	present	 in	 less	
than	60%	of	sporadic	sarcomas,	and	as	low	as	20%,	(10,	15,	22-25)	implying	that	disrupted	
p53	 may	 not	 be	 required	 for	 their	 formation,	 and	 that	 sarcoma	 etiology	 may	 be	
considerably	 varied.	 More	 specifically,	 sarcomagenesis	 may	 occur	 by	 two	 divergent	
mechanisms,	one	that	is	p53-mediated,	and	one	that	is	p53-independent,	and	consideration	
of	 only	 one	of	 these	mechanisms,	 such	 as	 in	 LFS	 tumors,	with	 germline	p53	drivers,	may	
improve	 detection	 of	 additional	 sarcoma	 risk	 factors.	 	 Normally,	 p53	 abrogates	 tumor	
growth	in	part	by	helping	cells	to	sense	cellular	stresses	such	as	hypoxia	and	DNA	damage,	
and	 limit	 cell	 proliferation	 under	 conditions	 where	 genomic	 integrity	 is	 likely	 to	 be	
compromised.		However,	when	p53	is	lost,	the	loss	of	these	protective	aspects	can	lead	to	
the	accumulation	of	oncogenic	mutations,	as	well	as	unchecked	cell	proliferation,	leading	to	




p53	 is	 known	 to	 be	 regulated	 by	 a	 variety	 of	 regulators,	 including	 the	 negative-
regulator	 MDM2.	 	 MDM2	 is	 an	 E3-ubiquitin	 ligase	 that	 specifically	 ubiquitinates	 p53,	
exporting	it	out	of	nucleus,	and	marking	it	for	degradation	(27-29).	Moreover,	MDM2,	as	a	
p53-inducible	 gene,	 is	 closely	 correlated	 with	 p53	 levels	 in	 normal	 cells.	 	When	 working	
appropriately,	 these	 combine	 to	 form	 an	 auto-regulatory	 loop,	 designed	 to	maintain	 low	
levels	 of	p53	 in	 the	 absence	of	 stress.	On	 the	 flip-side,	 during	 periods	 of	 stress	 and	DNA	
damage,	p53	and	MDM2	 are	both	phosphorylated,	preventing	 their	 interaction	with	each	
other,	thus	stabilizing	p53	(30-34).		In	some	cases,	this	stabilization	has	been	shown	to	be	an	
important	step	in	tumorigenesis,	particularly	when	there	is	mutant	p53,	such	as	in	LFS	(35).	
In	 addition,	 work	 by	 several	 groups	 has	 implicated	 a	 polymorphism	 in	 MDM2	
(SNP309)	as	a	risk	factor	across	several	cancer	types,	including	colorectal,	breast,	lung,	and	
brain	 among	many	 others	 (36-39).	 	 In	 conjunction	with	 LFS	 or	 in	 sporadic	 sarcomas,	 the	
presence	of	the	MDM2	SNP309	polymorphism	appears	to	accelerate	tumor	formation	(37,	
40-42).	The	results	of	meta-analyses	have	only	continued	to	affirm	that	there	is	evidence	for	






This	 idea	was	 first	 noted	when	 some	 tumors	with	 point	mutations	 in	p53	were	 found	 to	
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have	elevated	levels	of	p53	in	cancer	cells	relative	to	controls	(43,	44),	suggesting	that	p53	













Figure	 3:	 Compilation	of	 published	data	 containing	p53	mutations,	 as	 generated	by	 the	






suppressor	 genes.	 	 In	 general,	 the	mutational	 landscape	 for	 tumor	 suppressor	 genes	 and	











Figure	4:	Lollipop	diagrams	 from	cBio	 (22)	depicting	 the	mutation	 frequency	across	 four	
genes.		Three	are	tumor	suppressors	(RB1,	NF1,	and	TP53)	and	one	is	an	oncogene	(BRAF).		
The	profiles	 for	 the	 first	 two	TSG	are	 representative	of	most	TSG.	 	The	 third	TSG,	TP53,	





In	 order	 to	 better	 understand	 the	 underlying	 genetics	 and	 epigenetics	 behind	
sarcomagenesis,	 we	 propose	 to	 use	 LFS	 as	 a	 model	 disorder.	 	 LFS	 is	 a	 rare,	 inherited,	
heterogeneous,	 cancer	 predisposing	 syndrome	 caused	 by	 mutations	 in	 the	 tumor	
suppressor	gene	p53	(70-80%	of	cases)	(55,	56)	with	a	high	prevalence	of	sarcomas	(20,	56,	
57,	58{,	59).	In	a	classic	LFS	pedigree	(Figure	5),	we	see	characteristic	patterns	of	autosomal	
dominant	 inheritance	 (cancer	 is	 observed	 in	 every	 generation)	 and	 anticipation	 (age	 of	
onset	for	cancer	gets	younger	for	each	generation,	ranging	from	a	lung	cancer	at	age	61	in	
the	oldest	generation,	 to	a	variety	of	 cancers	 from	roughly	30-50	years	old	 in	 the	 second	
generation,	 to	 sarcomas	 in	 the	 first	 two	 decades	 of	 life	 in	 the	 third	 generation).		
	
Figure	 5:	 Canonical	 LFS	 pedigree	 with	 a	 TP53	 M133T	 mutation.	 	 The	 pedigree	 shows	
characteristic	patterns	of	autosomal	dominant	 inheritance,	anticipations,	a	broad	tumor	







spectrum,	 including	 breast	 cancer,	 brain	 cancer,	 lung	 cancer,	 and	 adrenocorticoid	 cancer	













• Additional	 first	 degree	 relative	 with	 cancer	 before	 the	 age	 of	 45,	 or	 a	
sarcoma	at	any	age	
2. Chompret	LFS	(61,	62)	requires	one	of	the	following	to	be	met.		Unless	otherwise	
stated,	 tumors	 in	 the	 LFS	 spectrum	 are	 considered	 to	 be:	 soft	 tissue	 sarcoma,	




breast	 cancer	 if	 the	 individual	 has	 breast	 cancer),	 before	 the	 age	 of	 56,	 or	
with	multiple	tumors	











Individuals	and	 families	meeting	 these	criteria	 turn	out	 to	have	genetic	alterations	 in	p53	
(p53-LFS)	in	about	70-80%	of	cases	(55).	
2.2 Evidence	for	a	Li-Fraumeni	Syndrome-like	disorder	









To	 date,	 no	 other	 mutations	 have	 been	 definitively	 associated	 with	 LFSL	 (56).	 In	









However,	 subsequent	 data	 accumulation	 on	 LFSL	 families	 did	 not	 find	 CHEK2	




pedigrees,	 including	 a	 polymorphism	 (Ile157Thr),	 and	 two	 that	 were	 somewhat	 rarer	
(Arg145Trp	 in	 a	patient	with	breast	 cancer	 and	a	 sarcoma,	 and	Arg3Trp	 in	 a	patient	with	
brain	cancer)	(72).	Sodha	et	al.	found	CHEK2	variants	in	3	of	26	families,	but	these	included	
a	synonymous	variant,	an	intronic	variant	which	does	not	appear	to	impact	splice	sites,	and	
a	 3-bp	 deletion	 in	 exon	 3,	 thus	 continuing	 to	 suggest	CHEK2	may	 not	 be	 an	 LFSL	 cancer	
predisposition	gene	(69).	
Expanding	the	pedigrees	tested	beyond	LFS/LFSL	for	CHEK2	mutations,	 including	 in	
familial	 breast	 cancer	 cohorts,	 did	 find	 excess	 risk	 for	 several	 cancers,	 including	 prostate	
(73),	colon	(74),	kidney	(73),	and	breast	cancer	(74,	75),	of	which	only	breast	is	a	canonical	
LFS/LFSL	 tumor	 (56).	 	However,	 they	did	not	 find	 similar	upticks	 in	 sarcomas	and	adrenal	
cortical	tumors	(73).		The	variant	is	fairly	common	in	the	general	population	(MAF	is	about	
1%),	and	therefore	present	 in	some	unaffected	women,	 leading	to	the	premise	that	 it	 is	a	
low-penetrance	 breast	 cancer	 risk	 allele.	 	 Moreover,	 the	 deletion	 is	 enriched	 in	 breast	
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cancer	families	that	are	BRCA1/BRCA2-negative	(74).	Therefore,	despite	some	ambiguity	in	
the	 literature,	 the	 general	 consensus	 has	 emerged	 that	 CHEK2	 should	 no	 longer	 be	
considered	a	cause	of	LFS/LFSL	(76).		
2.3.2 p53	UTR	
The	 majority	 of	 LFS-related	 research	 has	 focused	 on	 coding	 mutations	 in	 p53.		




An	 additional	 locus	 for	 LFSL	 was	 mapped	 by	 linkage	 to	 1q23	 (65).	 	 In	 this	 study,	
linkage	 analysis	 using	 microsatellite	 markers	 was	 completed	 across	 62	 constitutive	 DNA	
samples	over	 four	 LFSL	pedigrees,	and	mapped	a	10-Mb	region	with	a	 significant	positive	
LOD	score	(Figure	7).		Moreover,	although	the	authors	assumed	that	these	four	families	did	
not	necessarily	have	the	same	predisposing,	 locus,	a	heterogeneity	LOD	score,	the	highest	
seen	across	 the	genome,	 suggested	 that	 two	 families	 (STS200	and	STS027)	 contributed	 in	
this	 region,	 with	 the	 STS200	 family	 showing	 stronger	 linkage.	 As	 of	 December	 2017,	

















were	 selected	 relative	 to	 known	 function	 and	 potential	 relevance	 to	 cancer.	 	 Sanger	





STS200-032,	 each	 of	 whom	 had	 cancer,	 as	 well	 as	 a	 fourth,	 STS200-009,	 a	 married-in	
founder,	which	served	as	a	negative	control	(Figure	8).	
	
Figure	 8:	 Non-p53	 LFS	 pedigree	 with	 linkage	 in	 1q23.	 	 Initial	 Sanger	 sequencing	 was	
performed	 on	 three	 individuals	 in	 the	 latest	 generation,	 all	 with	 cancer	 (STS200-032,	
STS200-017,	and	the	proband,	STS200-000),	plus	a	married-in	control	(STS200-009).			
To	analyze	Sanger	data,	we	used	a	program	called	“Mutation	Surveyor”	(79),	which	
automatically	 identifies	 variants	 using	 the	 chromatogram	 traces.	 	 To	best	 ensure	 that	we	
were	 not	 missing	 anything,	 we	 ran	 the	 program	 with	 both	 a	 stringent,	 normal	 set	 of	
parameters,	as	well	as	with	a	more	relaxed	set	of	criteria	designed	to	limit	false	negatives.		
Appropriate	 criteria	 were	 discussed	 with	 SoftGenetics	 after	 we	 discovered	 some	
inconsistencies	in	their	algorithms.		
After	 manual	 verification	 using	 the	 chromatograms	 for	 clean,	 double	 peaks,	 we	
identified	 61	 unique	 heterozygous	 variants	 across	 the	 three	 individuals	 (STS200-000,	
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Initially,	 we	 sequenced	 two	 individuals,	 STS032-011,	 and	 STS200-017	 across	 both	 the	
Illumina	 (GAIIX)	 and	 Complete	 Genomics	 (CGI,	 v.	 2.0)	 pipelines	 to	 determine	 which	
sequencing	technology	we	wanted	to	move	forward	with.		Subsequently,	we	sequenced	one	












by	 lane.	Once	 separated,	 by	machine	 and	 lane,	 fastq	 files	were	 aligned	 using	 BWA-MEM	
(81).	 	 The	 resulting	 SAM	 files	 were	 cleaned	 and	 marked	 for	 duplicates	 using	 Picard	 to	
mitigate	potential	biases	introduced	during	amplification.		Samples	were	then	realigned	to	
adjust	for	potential	issues	near	indels,	followed	by	base-recalibration	using	GATK	(80).		For	







adaptor	 ligation	 technologies	 that	 introduced	 known	 2-bp	 gaps	 into	 the	 sequence	 reads.		
Because	most	existing	tools	were	designed	around	Illumina’s	more	contiguous	sequencing	
and	 without	 explicit	 gaps,	 adaptation	 of	 existing	 tools	 to	 CG	 data	 was	 problematic	 and	





In	 order	 to	 determine	 which	 platform	 we	 wanted	 to	 move	 forward	 with,	 we	
compared	 across	 a	 variety	 of	metrics,	 including	 overall	 data	 quality,	 and	 ability	 to	 detect	












Perhaps	 most	 strikingly,	 although	 most	 coverage	 plots	 depict	 a	 single,	 approximately	
normally	 distributed	 peak,	 this	 “poorer”	 STS200-017	 sample	 on	 Illumina	 produced	 a	
bimodal	peak	(Figure	10).	
Moreover,	we	also	saw	differences	when	looking	at	histograms	of	the	quality	scores	



























We	 then	 checked	 to	 see	 if	 the	 bottom-line	 was	 affected	 and	 if	 these	 apparent	
differences	in	quality	impacted	variant	calls.		Comparison	of	variant	calling	between	a	basic	
variant	calling	algorithm	setup	for	Illumina	(via	GATK,	UnifiedGenotyper	(82)),	and	Complete	
Genomics	 (Complete	 Genomics	 internal	 pipeline),	 saw	 dramatic	 differences	 when	
comparing	SNVs	for	STS200-017	(51%)	vs.	STS032-011	(85%).	
Taken	 together,	 these	 data	 suggested	 that	 the	 STS200-017	 sample	 for	 Illumina	







	 We	 next	 leveraged	 existing	 Sanger	 data	 for	 STS200-017	 that	 arose	 out	 of	 the	
functional	positional	candidate	screen.		Forty-eight	variants	in	the	Sanger	data	for	STS200-
017	 were	 identified	 using	 Mutation	 Surveyor,	 and	 were	 hand-validated	 individually	 by	
checking	the	chromatograms	for	double-peaks	in	both	the	forward	and	the	reverse	strand.		
Neither	 Illumina	 (44	 SNVs))	 nor	 Complete	 Genomics	 (45	 SNVs)	 identified	 all	 48	 SNVs;	
collectively	 they	were	able	to	 identify	46	total	SNVs.	All	“missed”	SNVs	were	homozygous	
for	the	reference	by	WGS.		The	data	suggest	that	both	Illumina	and	Complete	Genomics	are	









Several	 factors	 lead	 us	 to	 choose	 Illumina	 over	 Complete	 Genomics.	 	 First,	 the	
majority	of	the	Complete	Genomics	analysis	pipeline	is	not	well	understood,	and	exists	in	a	
black	 box.	 	 It	 requires	 the	 use	 of	 proprietary	 algorithms	 and	 analyses	 cannot	 be	 cross-
checked	with	 existing	 tools	 like	 BWA	 (81),	 Samtools	 (83),	 Picard	 (84),	 and	GATK	 (80,	 85).		
However,	at	the	time,	we	did	not	feel	as	 if	the	variant	calling	for	Complete	Genomics	was	
sub-par	or	compromised	due	to	these	differences.		Moreover,	although	Illumina	did	have	a	




Once	we	had	 selected	 Illumina	 to	move	 forward	with,	we	 sequenced	 the	proband	
STS200-000	 (HS2000).	 	 However,	 these	 data	 produced	 no	 compelling	 co-segregating	
variants	between	STS200-000	and	STS200-017.		To	better	ascertain	co-segregating	variants,	








Given	 the	 STS200	 pedigree	 (Figure	 8),	 we	 expected	 that	 a	 germline	 cancer	
predisposition	 variant	 could	 be	 driving	 the	 cancer	 and	 sarcoma	 phenotypes	 seen	 in	 the	




(1) We	 expected	 the	 variant	 to	 co-segregate	 between	 affected	 individuals	
with	 cancer	 and	 obligate	 carriers	 because	 it	 resembles	 an	 inherited	
cancer	syndrome	
(2) The	variant	would	be	 in	1q23,	particularly	given	 the	relatively	high	LOD	
score	





In	 summary,	 we	 initially	 focused	 on	 identifying	 co-segregating,	 rare	 (MAF<1%),	
heterozygous,	coding	SNVs	that	were	predicted	to	be	damaging	by	both	SIFT	 (<0.05),	 (86)	
and	Polyphen2	(PP2,	>0.453),	(87)	that	were	in	the	linked	region	in	1q23.			



















sufficient	 for	 an	 LFS	 diagnosis,	 imply	 that	 penetrance	 need	 not	 be	 significantly	 high	 in	
LFS/LFSL	families.		Moreover,	we	posit	that	given	the	overall	importance	and	prominence	of	
p53	in	cancer,	additional	LFSL	genes	are	likely	to	be	less	penetrant.		In	turn,	this	can	lead	to	
greater	 ambiguity	 in	 clinical	 ascertainment,	 and	 underreporting,	 such	 that	 in	 sum,	 less	







According	 to	several	databases,	 the	most	common	LFS	mutations	are	quite	 rare	 in	
the	 general	 population.	 	 We	 leveraged	 the	 IARC	 (89)	 database	 to	 determine	 the	 most	
frequently	mutated	codons,	and	then	looked	up	the	mutation	frequency	of	variants	in	these	
codons	 in	databases	such	as	Exome	Aggregation	Consortium	(ExAC)	 (90)	and	ESP	 (91).	 	 In	Figure	 13	we	 show	 a	 histogram	of	 the	most	 commonly	mutated	 codons	 in	 families	 that	
have	been	clinically	ascertained	as	classic	LFS	(strictest	criteria).		For	the	nine	most	common	
codons,	 I	 have	 included	 the	 codon	 number,	 and	 codon	 sequence.	 	 Above	 these,	 where	
present,	are	the	“MAF”	of	a	variant	in	that	codon	as	indicated	in	the	ExAC	database,	as	well	
as	the	incidence.		At	the	time	of	inquiry,	ExAC	contained	60,706	individuals.		Despite	the	fact	
that	 ExAC	 attempts	 to	 remove	 individuals	 affected	 by	 severe	 pediatric	 disease,	 it	 is	 clear	
that	p53	 variants	 are	occurring	 at	 some	 relative	 frequency.	Under	 the	exome	 sequencing	






codon	sequence.	 	Above	that	 is	a	representation	of	the	 incidence	 in	the	ExAC	database,	




may	be	more	common	 than	previously	appreciated	based	on	LFS	 incidence.	 	A	perusal	of	
exome	 databases	 found	 131	 individuals	 (0.2%	 of	 samples)	 with	 TP53	 mutations.	 	 These	
mutations	largely	fell	in	the	DNA	binding	domain	(~80%),	and	included	some	that	are	known	
to	 cause	 LFS,	 suggesting	 that	 numerous	 individuals	 may	 be	 carrying	 a	 non-penetrant	
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deleterious	 p53	 allele	 (92).	 Overall	 penetrance	 through	 close	 examination	 of	 the	 IARC	






order	 to	 cast	 a	wider	 net,	 and	 account	 for	 the	 possibility	 that	 variable	 penetrance	 could	
partially	explain	the	results,	we	opened	our	MAF	filter	to	account	for	variants	with	a	MAF	
less	 than	 5%.	 	 Although	 this	 could	 potentially	 lead	 to	 the	 identification	 of	 a	multitude	of	
variants,	 in	practice	maintaining	 the	absolute	 co-segregation	criterion	 is	highly	 restrictive.		
There	are	exactly	two	variants	that	both	co-segregate	with	a	MAF	threshold	of	less	than	5%,	
and	are	predicted	to	be	damaging	by	both	SIFT	and	Polyphen2	(Table	2).	




and	 differentiation	 of	 immune	 cells	 and	 has	 roles	 in	 both	 innate	 and	 adaptive	 immune	
response.	 	As	noted	 in	Table	 2,	although	the	SIFT	and	PP2	scores	are	both	promising	(i.e.	
predicted	to	be	deleterious	–	scores	are	close	to	0	and	1	respectively),	the	MAF	is	quite	high	
(close	 to	 4%	 in	 the	 1000	 genomes	 project	 (94),	 1KG)).	 	When	 considered	 under	 the	 ESP	
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(adjusted	 for	 ethnicity	 -	 the	 STS200	 family	 is	 of	Caucasian	descent),	 this	 number	 is	 about	
twice	as	high,	8.9%.		Such	a	high	MAF	is	perhaps	more	common	than	we	would	prefer	for	




NDUFS2	 encodes	NADH	dehydrogenase	ubiquinone	 iron-sulfur	protein	2.	 	NDUFS2	
catalyzes	 NADH	 oxidation	 within	 the	 mitochondria	 (including	 ubiquinone	 reduction	 and	
proton	 ejection).	 	 Much	 like	 SLAMF1,	 the	 MAF	 in	 both	 the	 1KG	 and	 ESP	 (for	 European	
Americans)	are	quite	high	for	what	is	understood	to	be	a	relatively	rare	disease.		Mutations	
in	 the	gene	NDUFS2	have	been	associated	with	Mitochondrial	Complex	 I	Deficiency.	 	This	
mitochondrial	 disorder	 has	 heterogeneous	 presentation,	 including	 macrocephaly	 (large	
head)	 and	 myopathies.	 	 However,	 cancer	 has	 never	 been	 associated	 with	 this	 disease,	
suggesting	that	NDUFS2	may	not	be	a	strong	candidate	for	additional	follow-up.	
To	 best	 determine	 if	 these	 variants	were	 viable	 candidates,	we	 performed	 Sanger	
sequencing	to	(a)	confirm	the	variant	in	the	7	individuals	with	WGS,	and	(b)	to	test	for	co-
segregation	 in	 additional	 members	 of	 the	 pedigree.	 	 In	 SLAMF1,	 the	 married-in	 founder	
turned	 out	 to	 have	 the	 mutation	 of	 interest.	 	 In	 NDUFS2,	 two	 obligate	 carriers	 and	 an	






A	 second	 possibility	 is	 that	 SIFT	 (86)	 and	 PP2	 (87)	 are	 imperfect	 prediction	
algorithms	and	that	requiring	a	mutation	to	be	“damaging”	across	both	algorithms	may	lead	
to	premature	exclusion	of	variants.		SIFT	predictions	are	based	on	amino	acid	conservation	
in	 closely	 related	 sequences.	 	 In	 contrast,	 PP2	 emphasizes	 the	 impact	 of	 the	 change	 on	
protein	structures.		In	practice,	SIFT	and	PP2	do	not	always	agree	with	one	another,	and	it	
may	 be	more	worthwhile	 to	 consider	 variants	 predicted	 to	 be	 damaging	 by	 one	or	more	
algorithm(s).	 	 Moreover,	 known	 LFS	 variants	 such	 as	 p53	 M133T	 sometimes	 may	 be	
predicted	to	be	relatively	benign	(initially	 the	variant	had	a	PP2	score	of	0.148,	but	under	
the	most	recent	iteration,	it	is	now	0.858).		For	example,	if	a	cancer	predisposing	germline	
mutation	 is	 human-specific;	 in	 this	 case,	 we	 would	 expect	 a	 SIFT	 score,	 which	 is	 based	
primarily	on	conservation	to	be	relatively	high	(i.e.	benign).		To	cast	the	widest	possible	net,	
we	then	changed	the	stringency	in	SIFT/PP2	to	not	require	any	thresholds,	although	we	did	






Of	 these,	 there	were	 three	 new	 genes,	 IFI16,	 ADAMTS4	 and	OLFML2B.	 ADAMTS4	
encodes	disintegrin	and	metalloproteinase	with	thrombospondin	motifs	4	and	is	known	to	
degrade	 aggrecan	 in	 cartilage	 and	 brevican	 in	 the	 brain	 and	 has	 a	 thrombospondin	 type	
motif	(TSR)	that	binds	to	the	ECM.	(95)	ADAMTS4	is	thought	to	possibly	play	roles	in	arthritis	




the	other	variants	considered	so	 far,	 is	 reasonably	polymorphic,	but	 is	actually	one	of	 the	
candidate	 genes	 previously	 identified.	 	 IFI16	 is	 a	 member	 of	 the	 p200	 family,	 known	 to	
inhibit	cell	cycle	progression.		Moreover,	loss	of	IFI16	has	been	associated	with	breast	and	
prostate	cancers	(97).			
There	 have	 been	 no	 papers	 published	 on	 Olfactomedlin-like	 2B	 (OLFML2B),	 but	
olfactomedlins	 have	 been	 implicated	 in	 development	 and	 organization	 of	 the	 nervous	





Without	 any	 particularly	 strong	 candidates	 so	 far	 identified	 in	 1q23,	 we	 next	













One	other	possibility	 is	 that	 the	 family	 contains	 a(nother)	 phenocopy,	 or	 that	one	
affected	individual	could	be	homozygous,	or	even	hemizygous	for	the	mutation	of	interest.		
It	 would	 be	 unlikely,	 but	 not	 impossible,	 for	 example,	 for	 both	 parents	 to	 have	 the	
mutation,	 or	 for	 there	 to	 have	 been	 a	 gene	 conversion	 event	 prior	 to	 DNA	 sampling.		
Instead	 then	 of	 asking	 FamSeq	 to	 identify	 all	 variants	 that	 had	 possible	 heterozygous	
mutations	 in	 6	 of	 6	 affected/obligate	 carriers,	 we	 instead	 asked	 FamSeq	 to	 identify	 all	
variants	 that	 seemed	 to	 be	 heterozygous	 in	 5	 of	 6	 individuals.	 Under	 the	 more	 relaxed	
criteria	 listed	 above,	 we	 generated	 another	 list	 of	 candidate	 variants,	 with	 one	 notable	
addition,	a	mutation	in	ARHGAP30	(Table	4).	
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to	 sequence	 additional	 members	 of	 the	 pedigree	 confirmed	 that	 co-segregation	 was	
otherwise	 complete.	 	 There	 was	 one	 seeming	 outlier:	 a	 bladder	 cancer	 patient	 (STS200-
102),	who	was	WT	for	the	mutation.		However,	based	on	the	linkage,	he	shared	very	little	of	






Figure	 15:	 Sanger	 sequencing	 of	 additional	 members	 of	 the	 pedigree	 confirms	 co-
segregation	of	 the	mutation	 in	ARHGAP30,	 including	 the	homozygous	result	 for	STS200-
032.	 	 Based	 on	 the	 linkage,	 we	 expected	 one	 of	 STS200-108	 or	 STS200-109	 to	 be	 a	




In	 order	 to	 rule	 out	 the	 unlikely	 possibility	 that	 the	 linkage	 was	 incorrect,	 we	
expanded	 the	 search	 to	 include	 variants	over	 the	entire	 genome.	 	 This	 time,	 because	we	
were	not	in	the	linked	region,	we	changed	the	parameters	to	exclude	STS200-019,	because	












To	 definitively	 determine	 if	 any	 of	 these	 variants	 were	 also	 candidate	 germline	 cancer	
predisposition	 variants,	 we	 tested	 additional	 samples	 from	 the	 pedigree	 to	 see	 if	 they	
maintained	co-segregation.			
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the	 STS200	 pedigree.	 	 However,	 this	 exact	 variant	 is	 annotated	 in	 the	 ClinVar	 database	








to	be	polymorphic,	 the	majority	of	which	were	 intronic.	 	However,	we	note	 that	 some	of	





The	 authors	 hypothesize	 that	 regions	 that	 almost	 never	 have	 a	 variant	 are	 somehow	





a	p53	UTR-variant	 that	 co-segregated	with	disease	 in	an	LFSL	 family	where	p53	had	been	
previously	 ruled	 out	 (77).	 	 To	 check	 to	 see	 if	 the	 STS200	 family	 contained	 this	mutation	
(rs78378222),	 we	 checked	 the	 WGS	 data,	 and	 used	 Sanger	 sequencing,	 finding	 that	 all	
tested	individuals	were	WT	for	the	UTR-variant.			
3.4 More	in-depth	investigation	of	“known”	sarcoma	risk	factors		
Several	 genes	 have	 been	 associated	 with	 sarcomas,	 either	 through	 a	 study	 of	
individual	 subtypes,	 or	 through	 broader	 analysis	 of	 targeted	 sequencing.	 When	 they	
analyzed	1,162	sarcoma	probands,	Ballinger	et	al.	found	that,	overall,	probands	were	more	
likely	 to	 have	multiple	 pathogenic	 variants	 relative	 to	 controls,	 and	 that	 these	were	 best	





Table	 7:	 List	 of	 genes	 associated	 with	 sarcomas,	 either	 through	 hereditary	 cancer	
syndromes,	CN	changes,	or	as	fusion	transcripts.	
ACP5	 COL1A1	 GLMN	 NFATc2	 SMARCA4	
ACTB	 COL1A2	 GNAS	 NFIB	 SMARCA5	
ACVR1	 COL6A3	 H19	 NR4A3	 SMARCB1	
AIP	 CREB1	 HAS2	 NTRK3	 SOS1	
AKT1	 CREB3L1	 HEY1	 PATZ1	 SP3	
ALK	 CREBBP	 HMGA2	 PBX1	 SQSTM1	
ANTXR1	 CSF1	 HRAS	 PDGFB	 SS18	
ANTXR2	 CTNNB1	 IDH1	 PDGFRA	 SSX1	
APC	 CXCR7	 IDH2	 PIK3CA	 SSX2	
ASPSCR1	 DDIT3	 IGF1R	 PLAG1	 SSX4	
ATF1	 DICER1	 IGF2	 PMS2	 STARD13	
ATIC	 DUX4	 INI1	 PORCN	 T	
BCL2	 EBF1	 KCNQ1OT1	 POU5F1	 TAF15	
BCOR	 ERCC2	 KDR	 PRKAR1A	 TEK	
BLM	 ERG	 KIT	 PTCH1	 TFE3	
BRAF	 ETV1	 KRAS	 PTEN	 TIE1	
BUB1B	 ETV4	 LEMD3	 PTEN		 TNFRSF11A	
C11orf95	 ETV6	 LHFP	 PTH1R	 TNFRSF1A	
CAMTA1	 EWSR1	 MAP2K1	 PTPN11	 TP53	
CCNB3	 EXT1	 MDM2	 RANBP2	 TPM3	
CCND1	 EXT2	 MEN1	 RB1	 TPM4	
CCNE1	 FEV	 MID1	 RECQL3	 TSC1	
CDH11	 FGFR4	 MKL2	 RECQL4	 TSC2	
CDK4	 FH	 MTAP	 RET	 USP6	
CDKN1C	 FLI1	 MYH9	 ROR2	 VGLL3	
CDKN2A	 FLT1	 MYOCD	 SDD	 VHL	
CDKN2B	 FOSL1	 NBN	 SDHB	 WRN	
CHEK2	 FOXO1	 NCOA2	 SDHC	 WT1	
CIC	 FUS	 NF1	 SDHD	 WWTR1	














To	 next	 determine	 if	 this	 variant	 was	 more	 widely	 relevant,	 we	 used	 Sanger	
sequencing	to	test	probands	from	other	LFSL	pedigrees	(where	p53	was	ruled	out)	to	see	if	
they	had	 the	exact	 same	mutation	 in	ARHGAP30.	 	We	 tested	6	probands	 from	Creighton	
University,	27	probands	 from	MD	Anderson	Cancer	Center	 (including	STS200),	9	probands	
from	Ohio	State	University,	and	6	probands	from	the	National	Cancer	 Institute	 (NCI)	 for	a	




p53,	 several	hotspot	mutations	occur	 in	CpG	sites,	 such	as	 those	at	codons	175,	248,	and	
273,	 with	 deamination	 and	 G!A	 transitions	 being	 common	 (105).	 	 Our	 variant	 in	
ARHGAP30,	 GTTCGGC[G/A]AACCCAG,	 also	 occurs	 in	 a	 CpG	 site	 and	 may	 arise	 due	 to	




To	 test	 statistically	 if	 these	 LFSL	 families	 were	 enriched	 for	 the	 mutation	 of	
ARHGAP30,	we	used	to	a	Poisson	approximation	based	on	two	reported	allele	frequencies.		
The	 dbSNP	 database	 contained	 the	 lowest	 reported	 MAF	 (0.86%),	 while	 the	 ESP	 (for	
European	 Americans)	 contained	 the	 highest	 MAF	 (2.72%).	 	 Using	 this	 information,	 we	
counted	 the	 number	 of	 cases	 we	 would	 expect	 to	 see	 on	 average,	 for	 48	 samples,	 and	
computed	a	one-sided	p-value	 to	determine	 the	 likelihood	 that	we	 saw	4	or	more	 cases.		
For	dbSNP,	this	corresponds	to	a	p-value	of	8.7e-4,	and	for	4.4e-2	for	ESP,	suggesting	that	
these	LFSL	pedigrees	are	enriched	for	the	mutation	in	ARHGAP30.	
The	 result	 of	 having	 multiple	 families	 with	 the	 same	 exact	 mutation	 in	 a	 tumor	
suppressor	 gene	 is	 unexpected,	 but	 not	 impossible.	 	 The	majority	 of	 well-studied	 tumor	
suppressor	 genes	 and	 oncogenes	 follow	 a	 specific	 pattern.	 	 Oncogenes	 are	 typically	
recurrently	 mutated	 at	 specific	 amino	 acids,	 while	 tumor	 suppressor	 genes	 have	 flatter	
mutational	 profiles,	 with	 mutations,	 especially	 protein-truncation	 mutations,	 occurring	










DNA	 and	 formalin-fixed	 paraffin-embedded	 (FFPE)	 blocks	 from	 Dr.	 Lynch	 to	 test	 for	 co-
segregation	 in	 this	 family.	 	For	 the	DNA	samples,	we	used	Sanger	sequencing,	but	 for	 the	
FFPE	 blocks,	 we	 used	 pyrosequencing.	 	 Samples	 from	 this	 pedigree	 included	 FFPE	 blocks	
from	before	1972,	and	contained	highly	cross-linked	and	fragmented	DNA,	making	Sanger	
sequencing	 difficult.	 	 Therefore,	 using	 pyrosequencing,	 which	 amplifies	 a	 much	 smaller	
fragment	 (~100-bp	 vs.	 500-800-bp)	 was	 advantageous.	 	 Even	 with	 the	 use	 of	
pyrosequencing,	we	found	that	we	needed	to	use	a	nested	PCR	in	a	clean	room	to	generate	





children	with	breast	cancer	 (F,	diagnosed	at	35	y.o.,	dead	at	36	y.o.)	and	 lung	cancer	 (M,	
diagnosed	 at	 32	 y.o.	 dead	 at	 32	 y.o.).	 	 We	 have	 requested	 a	 second	 sample	 from	 this	
individual	for	retesting,	but	have	not	yet	received	it.			
We	 received	 one	 FFPE	 tumor	 sample	 from	Creighton	University;	when	 tested	 this	
tumor	had	retention	of	heterozygosity	(ROH).		However,	we	note	that	loss	of	heterozygosity	
(LOH)	may	not	be	required	for	tumorigenesis.		First,	given	the	limited	number	of	studies	on	
ARHGAP30,	 it	 is	not	 clear	 if	 the	gene	could	be	haploinsufficient.	 	 Secondly,	 in	 sequencing	
both	 human	 and	mouse	 LFS	 tumors	 with	 p53	mutations,	 it	 is	 clear	 that	 p53	 LOH	 is	 less	
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common	 than	 otherwise	 appreciated.	 	 Therefore,	 we	 do	 not	 consider	 this	 single	 result	
showing	ROH	to	rule	out	ARHGAP30	from	additional	consideration.	
To	 summarize,	 the	 same	 ARHGAP30	 mutation	 is	 found	 across	 multiple	 LFSL	
pedigrees,	and	appears	to	be	enriched	in	LFSL	families	over	the	general	population.	For	the	
most	part	co-segregation	is	complete	in	the	families	we	have	tested	so	far.		Taken	together	
these	 data	 suggest	 that	 this	 specific	 variant	 in	 ARHGAP30	 is	 a	 strong	 candidate	 for	 a	























drawn	 from	 it.	 	 However,	 data	 with	 controls	 indicate	 that	 when	WT	 ARHGAP30	 (short	




Figure	 17:	 Figure	 3a	 from	Naji	 et	 al.	 2011.	 	 In	 the	 presence	 of	 the	 overexpressed	 short	
isoform	of	WT	ARHGAP30,	cells	appear	significantly	more	rounded	relative	to	untreated	
controls,	 and	 may	 have	 more	 migratory	 capacity.	 	 Used	 with	 permission:	 Naji,	 L.,	 D.	
Pacholsky,	and	P.	Aspenstrom.	2011.	ARHGAP30	is	a	Wrch-1-interacting	protein	involved	
in	 actin	 dynamics	 and	 cell	 adhesion.	 Biochemical	 and	 biophysical	 research	
communications	409:	96-102.	L/N	4294720235318.	
The	 second	paper,	by	Wang	et	 al.	 is	 significantly	more	 comprehensive	 (100).	 They	
showed	 that	 ARHGAP30	 was	 significantly	 downregulated	 in	 colorectal	 cancer	 vs.	 normal	





Figure	 18:	 Figure	 1a,c	 from	 Wang	 et	 al.	 2014.	 	 a)	 qRT-PCR	 data	 showing	 ARHGAP30	
expression	was	downregulated	 in	 colorectal	 cancer	 vs.	normal	 tissues.	 	 c)	Kaplan-Meier	















Wang	 et	 al.	 tested	 the	 impact	 of	 stable	 overexpression	 of	 ARHGAP30	 across	 three	main	
ideas:	cell	proliferation,	cell	migration,	and	apoptosis,	finding	that	cells	transfected	with	WT	





of	 LoVo	 cells	 is	 decreased	 when	 ARHGAP30	 is	 over-expressed.	 	 Moreover	 this	
functionality	 seems	 to	be	 independent	of	 the	GAP	domain	 since	 the	effect	 in	 the	R55A	
mutant,	which	has	no	GAP-relation	functionality.		b)	HCT116	cells	also	grow	more	slowly	














null	 HCT116	 cells	 were	 used,	 this	 effect	 was	 abrogated,	 and	 p53	 target	 genes	 were	 not	












treated	 with	 etoposide	 had	 upregulation	 of	 p53	 target	 genes,	 and	 that	 this	 effect	 was	
attenuated	 by	 knockdown	of	WT	ARHGAP30.	 	Moreover,	 chromatin	 immunoprecipitation	
(ChIP)	analysis	of	cells	with	ARHGAP30	knockdown	and	etoposide	treatment	found	reduced	
binding	 of	 p53	 to	 p21,	 BAX,	 NOXA,	 and	 PUMA.	 This	 effect	 seemed	 to	 be	 driven	 by	
acetylation	 of	 p53	 at	 Lys382	 (K382),	 which	 is	 known	 to	 activate	 p53.	 	 	 Additional	
experimentation	 found	 that	 this	 effect	 was	 abrogated	 by	 knockdown	 of	 p300,	 and	 that	







Given	 our	 strong	 genetic	 evidence,	 including	 co-segregation	 and	 recurrence,	
implicating	ARHGAP30	R1017Q/R806Q	as	a	putative	cancer	predisposition	mutation,	as	well	
as	 the	 functional	 data	 presented	 by	 Wang	 et	 al.	 (100),	 we	 next	 tested	 if	 our	 mutation	
conferred	 any	 cancer-like	 advantages	 when	 transfected	 in	 vitro.	 	 In	 line	 with	 previous	
experiments,	we	first	sought	to	test	cell	migration	and	cell	proliferation.	




mutation,	 but	weren’t	 able	 to	 find	 any.	 	Therefore,	we	 picked	 the	 cell	 line	with	 sarcoma	





Cell	Line	 Tissue	 p53	status	 ARHGAP30	status	
HEK293T	 Kidney	 p53	R280S	(108)w	 WT,	Norm.	Expr.	




HT-1080	 Fibrosarcoma	 p53	WT	 WT,	High	Expr.	
Hs.	863T	 Ewing	Sarcoma	 p53	WT	 WT,	Low	Expr.	
	
Given	that	LFSL	arises	out	of	a	p53	WT	background,	we	would	certainly	expect	to	see	






















Figure	 22:	 Western	 Blot	 performed	 in	 conjunction	 with	 Kevin	 Tracy	 (CPRIT	 summer	
student)	 comparing	 the	 efficacy	 of	 transfecting	 U-2	 OS,	 HT-1080,	 HEK293T,	 and	 Saos-2	















cells	 came	 off	 in	 sheets,	 and	 were	 unable	 to	 limit	 the	 scratch	 to	 a	 single	 field-of-view.	
	





in	 an	 LFSL	 patient	 without	 inherited	 TP53	 mutations.	 	 In	 these	 cells,	 we	 see	 the	 most	
dramatic	 change	 of	 all	 tested	 cell	 lines	 when	 comparing	 the	 wound	 healing	 capability	
between	transfection	with	WT	and	mutant	plasmids.		Cells	transiently	transfected	with	WT	
ARHGAP30	 (both	 long-	 and	 short-isoforms)	 show	 limited	 ability	 to	 close	 the	 wound.	 	 In	
contrast,	 the	 mutant	 L-ARHGAP30	 shows	 pronounced	 ability	 to	 close	 the	 gap	 with	 the	
shorter	 isoform	 showing	more	 limited,	 but	 still	 significant	 ability	 to	 close	 the	 intervening	
space	(Figure	24).			Given	that	U-2	OS	cells	are	WT	for	p53,	these	data	demonstrate	that	the	























under	 transient	 transfection	of	 the	mutant	 relative	 to	WT	controls,	although	 this	effect	 is	
not	as	dramatic	as	in	U-2	OS.		One	distinct	difference	here	though	is	that	the	short-isoform	
shows	 increased	closure	 relative	 to	 the	 long-isoform	 (Figure	 25).	 	Given	 that	Saos-2	cells	
are	null	 for	p53,	these	data	suggest	that	the	effect	 is	present	even	 in	the	absence	of	p53.	








Similar	 to	U-2	OS	 cells,	 HT-1080	 cells	 are	WT	 for	p53	 (53,	 107).	 	 However,	 in	 contrast	 to	
previous	data,	the	endogenously	high	ARHGAP30	HT-1080	cells	closed	remarkably	quickly,	
including	when	the	WT-ARHGAP30	plasmids	are	overexpressed,	having	closed	after	just	24-
hours	 (Figure	 26).	 	 Notably,	 even	 the	 untreated	 (?)	 control	 (with	 endogenously	 high	
ARHGAP30	 levels)	 is	 able	 to	 somewhat	 close	 the	wound	 (though	not	 completely).	 	Again,	







































to	 a	 control,	 they	 did	 appear	 to	 abolish	 the	 slower	 growth	 rates	 observed	 when	
overexpressing	WT	ARHGAP30.	
	





In	 contrast,	 in	 U-2	 OS	 cells,	 we	 saw	 a	much	more	muted	 response,	 although	 the	 overall		
phenotype	 is	 similar	 to	 293T	 cells.	 	 Cells	 transfected	with	WT	ARHGAP30	 did	 grow	more	












not	 for	 the	 short	 isoform.	 	 Namely	 transfection	 with	WT	ARHGAP30	 suppresses	 growth,	

















Co-segregation	 analysis	 was	 used	 to	 isolate	 a	 plausible	 LFSL	 gene.	 	We	 identify	 a	
reasonably	 rare,	 co-segregating	 mutation	 in	 1q23	 that	 is	 recurrent	 across	 multiple	 LFSL	








what	 happens	 to	migration	 in	 an	 ARHGAP30	 overexpression/p53	 null	 background.	 If	 cell	
migration	is	abrogated	alongside	apoptosis	and	proliferation	in	p53	null	HCT116	cells,	it	runs	
in	 direct	 contrast	 to	 what	 we	 observe	 in	 Saos-2	 cells.	 	 In	 Saos-2	 cells	 with	 the	 cancer	
predisposing	 mutation,	 cells	 are	 able	 to	 close	 the	 cap	 relative	 to	 overexpression	 of	 WT	
ARHGAP30.	 	This	suggests	 that	not	only	does	 the	ARHGAP30	p.R>Q	mutation	have	a	p53-
independent	means	of	 impacting	tumorigenesis,	but	also	that	 it	may	be	a	gain-of-function	
mutation.				
	 Consistent	 with	 this	 interpretation,	 we	 observe	 wound	 healing	 and	 proliferation	




further	 weight	 on	 a	 p53-independent	 mechanism	 for	 mutant	 ARHGAP30.	 	 However,	 we	




this	 cell	 line	 relative	 to	 other	 cell	 lines	 that	 we	 used	 (Figure	 33),	 and	 has	 no	 known	
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30	 hours,	 perhaps	 suggesting	 that	 these	 cells	 have	 acquired	 some	 sort	 of	 escape	
mechanism.	 	Moreover,	 additional	WT	ARHGAP30	exacerbates	 the	 closure	 relative	 to	no-
treatment	controls,	which,	on	its	own,	implies	ARHGAP30	acts	more	like	an	oncogene	in	this	


















































blot	 showing	protein	 levels	of	p53	and	p21	 in	 STS200-derived	 cells.	 	 LBCLs	 from	STS200	






We	 next	 considered	 potential	 relevance	 to	 sporadic	 sarcomas.	 	 Under	 cBio,	
ARHGAP30	 is	 recurrently	 mutated	 in	 just	 0.7%	 of	 all	 samples,	 and	 our	 specific	 germline	
variant	 has	 not	 yet	 been	 called	 in	 publicly	 available	 somatic	mutation	 data.	 	 However,	 it	
turns	out	that	our	mutation	is	assayed	by	SNP	arrays.	 	We	worked	with	Dr.	Keith	Baggerly	
and	 Dr.	 Ying	 Wang	 to	 acquire	 these	 data	 and	 to	 generate	 a	 list	 of	 tumors	 and	 their	
genotypes.		We	sorted	by	genotype,	letting	the	A-allele	stand	for	the	WT-allele,	and	the	B-
allele	 for	 the	mutant-allele.	 	We	 then	 counted	 total	 alleles,	 and	 ran	 a	 one-sided	 Poisson	
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approximation	 to	 see	 how	 likely	we	were	 to	 uncover	 at	 least	 that	many	 alleles.	 	We	 ran	
these	 data	 under	 two	 conditions,	 once	 for	 the	 lowest	 reported	MAF	 (0.86%,	 dbSNP)	 and	
once	 for	 the	 highest	 (2.72%,	 ESP-EA).	 	 At	 the	 lower	 allele	 frequency,	 multiple	 cancers	
appear	to	be	enriched	for	the	mutation,	but	when	using	the	ESP	as	a	baseline,	there	is	just	
one	 showing	 statistical	 significance,	 colorectal	 adenocarcinoma	 (COAD).	 	We	 further	note	
that	 for	 COAD	 tumors,	 there	 are	 seven	 tumors	with	 a	 “BB”	 genotype,	 versus	 six	with	 an	
“AB”	genotype	–	 these	data	 imply	 that	LOH	may	be	a	 reasonably	common	event	 in	 these	
tumors.	
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Table	 9:	 Table	 showing	 allele	 incidence	 of	ARHGAP30	 c.G>A,	 p.R>Q	 in	 TCGA	 SNP	 array	
data	 (data	 generated	 by	 the	 TCGA:	 “http://cancergenome.nih.gov”).	 	 p-values	 are	
calculated	 via	 a	 Poisson	 approximation	 to	 determine	 if	 we	 saw	 enrichment	 for	 the	





Despite	 these	 data,	 there	 are	 a	 couple	 of	 mitigating	 questions	 remaining	 to	 be	
answered.	 	 First,	 the	 co-segregation	 analyses	 suggest	 that	 co-segregation	 may	 not	 be	
canonically	complete.		However,	we	believe	there	are	plausible,	if	rare,	scenarios	that	could	
explain	these	seemingly	“outlying”	individuals.			
First,	 for	 the	 one	 individual	 in	 STS200	 that	 is	 homozygous	 for	 the	 mutation	 of	
interest	 (STS200-032),	 it	 is	 unlikely,	 but	 not	 impossible	 that	 she	 received	 a	mutant	 allele	
from	 both	 parents.	 	 Alternatively,	 she	 could	 have	 experienced	 an	 extremely	 early	 gene	
conversion	event	that	resulted	in	an	extended	stretch	of	LOH.		To	address	this	possibility	we	
used	our	WGS	data	and	looked	in	the	region	near	ARHGAP30	and	plotted	whether	variants	
were	 homozygous	 for	 the	 alternate	 allele	 (blue),	 or	 heterozygous	 for	 the	 alternate	 allele	
(red).	 	 If	 the	 sample	was	 homozygous	WT,	we	 left	 it	white/blank.	 	 In	 this	 region,	 it	 does	
appear	 as	 if	 the	 STS200-032	 sample	 is	 on	 average	more	 homozygous	 for	 the	 SNVs/SNPs	
interrogated	(Figure	35),	though	it	impossible	to	say	for	sure.		A	third,	related	possibility	is	
uniparental	 disomy	 (UPD),	 in	which	 two	 copies	 of	 the	 chromosome	 come	 from	 the	 same	
parent.		This	may	also	help	explain	some	of	the	other	heterozygous	mutations	in	this	region	






in	 blue	 and	white/blank.	 	 Heterozygous	 events	 are	 red.	 	 The	majority	 of	 samples	 have	
significant	 heterozygous	 variants	 in	 this	 region,	with	 the	 exception	 of	 STS200-032.	 	We	
feel	that	this	data	could	be	consistent	with	a	gene	conversion	event.	
In	 addition	 to	 STS200,	 one	 other	 co-segregation	 question	 remains	 under	
investigation.	 	One	theoretical	obligate	carrier	 in	 the	Creighton	pedigree	did	not	have	the	
ARHGAP30	mutation.	 	She	had	two	children	with	LFSL-associated	cancers	(breast	and	lung	
cancer,	 both	 before	 the	 age	 of	 40).	 	 However,	 she	 is	 in	 a	 more	 distant	 branch	 of	 the	
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pedigree,	 and	 it	 is	 possible	 that	 she	 has	 a	 second,	 non-ARGHAP30	 cancer	 predisposition	
gene.	 	 Alternatively,	 it	 is	 possible	 that	 the	 father	may	have	 carried	 a	 cancer-predisposing	
mutation;	however,	no	information	is	known	about	his	family.	
	 However,	 we	 do	 not	 consider	 the	 MAF	 a	 major	 sticking	 point.	 	 As	 previously	
discussed,	 emerging	 research	 suggests	 that	 germline	p53	variants	may	 be	more	 common	
than	previously	expected.	 	Thus,	 it	may	be	perfectly	 reasonable	to	have	a	more	common,	
less	 penetrant	 allele	 (p53	 or	 non-p53),	 even	 for	 a	 rare	 disease.	 	 Interestingly,	we	 do	 not	
observe	any	variants	 in	known	cancer	genes	–	 this	 implies	either	 that	ARHGAP30	has	 the	







recurrent,	 co-segregating,	 cancer	predisposition	gene	 in	 LFSL	 families.	 	However,	we	note	
that	 these	 data	 do	have	 some	mitigating	 question	marks.	 	 The	 variant	 is	 not	 overly	 rare,	
putting	it	in	line	with	a	previous	purported	LFSL	gene/mutation	CHEK2	1100delC,	and	in	the	
STS200	pedigree	has	an	unexpected	outlier,	 a	 single	homozygous	 case.	 	Moreover,	 in	 the	
one	tumor	we	have	been	able	to	sequence,	we	were	not	able	to	detect	LOH.		However,	we	
feel	that	there	are	plausible	explanations	for	each	of	these	scenarios	and	thus	do	not	derail	




We	 propose	 two	 fundamental	 ways	 to	 move	 forward	 with	 this	 project:	 First,	
sequence	 (non-p53)	 LFSL	 pedigrees	 lacking	 p.R806/1017Q	 mutations	 for	 additional	




explore	 the	 functional	 implications	 in	 vivo	 through	 the	 use	 of	 a	 mouse	 model.	 	 CRISPR	
technology	 has	 greatly	 impacted	 the	 ease	 and	 feasibility	 of	 generating	 mice	 with	 single	
point	mutations	such	as	in	the	ARHGAP30	RQ	variant.		Following	generation	of	appropriate	
mouse	model	 and	 cohort	with	 the	mutation(s)	 of	 interest,	we	 can	 the	 track	 and	observe	
tumor	 formation	 in	 the	mice.	 	Moreover,	 in	 conjunction	with	 this,	 it	will	 be	 important	 to	











Cancer	 has	 been	 attributed	 to	 a	 variety	 of	 factors,	 including	 germline	 cancer	
predisposition	 mutations,	 as	 well	 as	 somatic	 alterations.	 	 In	 the	 first	 portion	 of	 the	
dissertation,	we	leveraged	LFSL	to	identify	a	novel	germline	cancer	predisposition	mutation	
in	ARGHAP30.	 	 In	 the	second	portion,	we	 leverage	 tumors	 from	LFS	patients,	with	known	
p53	mutations,	 to	address	 the	potential	 contributions	of	 somatic	alterations.	 	Despite	 the	
ubiquity	of	p53	mutations	 in	human	cancers,	 some	 individuals	 in	 LFS	pedigrees	 (with	p53	
mutations)	do	not	develop	cancer	(56,	93),	or	develop	cancer	very	late,	suggesting	that	the	




The	 rarity,	 heterogeneous	 composition,	 and	numerous	 subtypes	of	 sarcomas	have	
complicated	 elucidation	 of	 genetic	 risk	 factors	 and	 driver	 mutations.	 	 A	 recent	 study	
implicates	ATM	and	ATR	as	risk	factors	(16),	but	lacked	the	statistical	power	to	definitively	
determine	one	way	or	the	other.		Moreover,	sequencing	done	by	the	TCGA	has	shown	that	
different	 sarcoma	 subtypes	 tend	 to	 have	 distinct	mutational	 profiles	 across	 the	 genome,	







Under	 LFS,	 sarcomas	 are	 a	 fairly	 common	 cancer,	 representing	 about	 25%	 of	 all	
tumors	 (13%	STS	 and	10%	OS,	Figure	 6)	 (53),	 suggesting	 perhaps	 that	 sarcomagenesis	 is	
largely	 driven	 by	 p53.	 	 However,	 p53	
alterations	 are	 present	 in	 only	 about	 half	 of	
all	sporadic	sarcomas	(10),	and	data	from	cBio	
seems	to	suggest	that	even	this	50%	number	
may	 be	 somewhat	 of	 an	 overestimate	
(depending	on	ascertainment)	(Figure	36).			
	
Figure	 36:	 Five	 sarcoma	 studies	 have	 been	
recorded	 in	 cBio,	 covering	 bone	 sarcomas	 (Ewing),	 and	 soft	 tissue	 sarcomas	 (mostly	
liposarcomas	 and	 leiomyosarcomas).	 	 From	 left	 to	 right,	 these	 comprise	 249,	 265,	 207,		
107,	 and	 43	 samples.	 	 These	 data	 suggest	 that	 alterations	 in	 p53	 are	 not	 particularly	
common	in	sarcomas,	topping	out	at	~60%.	
We	also	leveraged	cBio	to	check	for	tumors	with	alterations	in	any	of	MDM2,	MDM4,	and	
TP53	with	 about	 45%	 of	 sarcomas	 having	 an	 alteration	 in	 at	 least	 one	 of	 these	 genes,	
including	 a	 high	 percentage	with	MDM2	 amplification	 (Figure	 37).	 	 Taken	 together,	 and	
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for	 mutations	 in	 p53	 that	 are	 LOF	 (either	 by	 deletion,	 or	 point	 mutation)	 vs.	 GOF	 p53	
mutations.	 	Despite	 these	potential	 issues,	 it	 is	our	 long-term	hope	 that	 identifying	genes	
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associated	 with	 sarcomagenesis	 in	 LFS	 patients,	 will	 also	 have	 relevance	 to	 sporadic	
sarcomas,	and	other	cancer	types.	
6.4 A	Mouse	Model	of	LFS	May	Help	Identify	Important	Sarcomagenesis	Genes	
To	 overcome	 some	 of	 the	 limitations	 associated	 with	 sequencing	 only	 human	
tumors,	we	elected	to	pursue	and	take	advantage	of	a	mouse	model	of	LFS.		Several	mouse	
models	exist,	 including	p53-/-	mice	in	which	cancer	penetrance	is	100%,	with	most	cancers	
occurring	before	6	months.	 	These	mice	had	tumor	profiles	similar	 to	 that	of	LFS-patients	
(109).		However,	since	the	majority	of	LFS	patients	have	heterozygous	point	mutations,	we	
instead	elected	to	pursue	a	different	mouse	model.		This	model,	from	Dr.	Lozano,	contains	






emphasized	with	 the	use	of	 a	downloaded	copy	of	 the	 IARC	database	 (53)	 for	additional,	
more	granular	analysis.		These	data	include	a	“topography”	column,	which	contains	the	site	
of	 the	original	neoplasm,	as	well	as	 the	 type	and/or	codon	of	 the	p53	mutation.	 	We	can	
generate	similar	histograms	as	to	Figure	38,	except	selected	for	tumors	arising	out	of	“soft	
tissue”	 and	 “bone”	 –	 the	 majority	 of	 which	 are	 sarcomas,	 to	 see	 if	 germline	 R175H	
mutations	are	prominent	in	these	tumors.		Although	the	overall	mutation	profile	is	different	
than	 compared	 to	 all	 tumors	 (Figure	 38),	 the	 histograms	 in	 Figure	 39	 indicate	 that	
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alterations	at	codon	175	are	still	prominent	 in	both	osteosarcomas	 (Figure	 39A)	and	soft	
tissue	sarcomas	(Figure	39B).	
	






These	 ideas	 underlie	 several	 efforts,	 including	 COSMIC,	 and	 TCGA	 to	 catalog	 somatic	
variation	across	a	wide-range	of	tumors	(5,	110(111).	
However,	recurrence	alone	may	be	a	poor	metric.		Some	genes	or	genomic	regions	
may	be,	or	appear	 to	be,	hypermutable,	but	may	have	 little	 functional	 consequence.	 	For	
example,	olfactory	genes	and	large	muscle	genes	(e.g.	TTN)	often	appear	to	be	represented	
in	 lists	of	significantly	 recurrently	mutated	genes	 in	cancer	 (112,	113).	Respectively,	 these	
gene	 families	 are	 either	 not	 expressed	 in	 tumors,	 or	 due	 to	 their	 size	 are	 likely	 to	 have	
acquired	somatic	changes	by	chance	alone,	suggesting	that	recurrence	alone	is	insufficient	
or	 that	 it	 may	 misclassify	 some	 genes.	 	 Thus,	 separating	 out	 drivers	 from	 passengers	
remains	a	key	challenge.	





more	 readily	 generate	 LFS-associated	 sarcomas.	 	 Secondly,	 the	 mice	 will	 all	 have	 been	
raised	 in	 the	 same,	 shared	 environment,	 the	mouse	 facility.	 	 Thirdly,	 the	mice	will	 come	




arise	 out	 of	 species-specific	 genomic	 context.	Moreover,	 this	 comparative	 approach	 was	




via	 WGS	 or	 WES,	 it	 is	 clear	 that	 other	 changes,	 such	 as	 those	 in	 the	 transcriptome	 or	
methylome	 may	 significantly	 contribute	 to	 cancer	 (5,	 6,	 115).	 	 In	 fact,	 these	 data	 can	
support	each	other	when	done	 in	concert,	 to	provide	a	more	 layered,	nuanced	picture	of	






54),	 occurring	 in	 a	 subset	 of	 reasonably	 predictable	 genes	 (e.g.	 TP53,	 NF1,	 RB1,	 PTEN,	
BRCA1,	BRAF,	and	so	on).		However,	there	is	considerable	ambiguity	regarding	the	expected	
mutational	profile	of	LFS	sarcomas.	 	Many	LFS-associated	soft	 sarcomas	appear	 to	exhibit	
chromothripsis	and	CNAs,	particularly	soft	tissue	sarcomas	(10,	15),	and	exome	sequencing	
of	osteosarcomas	also	reveals	CNAs	to	be	common	(117,	118).		On	the	other	hand,	several	
genes	 with	 SNVs	 that	may	 impact	 osteosarcomagenesis	 have	 been	 identified	 (117,	 118).	
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However,	 in	 many	 p53-associated	 non-sarcoma	 tumors,	 we	 observe	 a	 mutator	
phenotype,	related	to	p53’s	function	as	the	guardian	of	the	genome,	in	which	these	tumors	
appear	 to	 acquire	 a	 plethora	 of	 variants,	 some	 of	 which	
	
Figure	40:	Tumor-free	survival	curve	of	p53+/H	(n=50)	and	p53+/+	 (n=20)	mice	from	our	
cohort,	 showing	 that	 that	 p53H/+	mice	 were	 more	 prone	 to	 develop	 tumors	 (p-value:	
6.37-e7).		Some	p53+/+	mice	developed	lymphomas,	particularly	in	the	thymus.	
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may	only	be	passengers	 (121,	122).	 	Thus	 it	may	be	unclear	what	we	should	expect	when	





that	 were	 p53	 WT.	 	 These	 mice	 were	 followed	 for	 a	 period	 of	 up	 to	 two	 years,	 with	
euthanasia	 performed	 for	 tumors,	 or	 other	 health	 conditions	 as	 needed.	 	 We	 collected	
multiple	 tissues	 from	 every	 mouse	 for	 pathology	 (including	 vastus	 lateralis,	 duodenum,	
pectoral	 and	 stomach	 muscles,	 diaphragm,	 kidney,	 spleen,	 heart,	 lung,	 liver,	 femur,	 and	




Figure	41:	Pie	graph	of	 tumor	distribution	 in	 the	p53	R172H	 cohort	 (n=50)	shows	a	high	
prevalence	of	lymphoma,	with	a	variety	of	sarcoma	types.	
Overall,	 mice	 with	 the	 LFS	 cancer-predisposition	 did	 develop	 tumors	 and	 had	
reduced	survival	 relative	 to	control	mice.	 	However,	we	did	observe	several	p53	WT	mice	
that	had	to	be	sacrificed	due	to	hyperpnea.		In	all	such	cases,	mice	were	visibly	hunched	and	
had	 lymphoma	 in	 the	 thymus	upon	dissection,	 suggesting	 that	 the	p53	WT	 C57BL/6	mice	
might	 have	 a	 predilection	 towards	 lymphomas,	 consistent	 with	 published	 results	 by	
Donehower	et	al.	(123).	
7.1.1 Lymphomas	and	sarcomas	were	the	most	common	tumor	types	
	 We	 sent	 all	 our	 tissues	 to	 Dr.	 Elizabeth	 Whitley	 (Pathogenesis,	 LCC)	 for	 full	
pathology.		The	majority	of	tumors	that	we	observed	in	our	mice	were	lymphoma	(including	
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in	 some	p53-WT	mice),	 or	 sarcoma,	with	 the	majority	 of	 these	 being	 osteosarcomas	 and	
histiocytic	 sarcomas.	 	Consistent	with	 the	notion	 that	 sarcoma	 types	 could	have	different	




a	 neoplasia	 composed	 of	 hematopoietic	 cells,	 that	 has	 historically	 been	 classified	 as	
lymphoma,	 and	 is	 typically	 ascertained	 only	 after	 extensive	 immunophenotypic	
characterization	 (124),	 making	 it	 a	 less	 compelling	 candidate.	 	 In	 addition,	 histiocytic	
sarcomas	are	not	considered	to	be	among	the	most	common	tumor	types	associated	with	
LFS	 in	 humans;	 in	 fact,	 in	 the	 IARC	 TP53	 database,	 there	 are	 no	 germline	 p53	 variants	
associated	 with	 histiocytic	 sarcomas.	 	 Therefore,	 we	 instead	 chose	 to	 sequence	
osteosarcomas	 and	 fibrosarcomas,	 leveraging	 additional	 samples	 that	 were	 previously	









Table	 10:	 Table	 of	 Mouse	 Sarcomas	 for	 NGS.	 	 VL	 –	 vastus	 lateralis,	 FR	 –	 femur,	 FS	 –	
fibrosarcoma,	OS	–	osteosarcoma.	 	 Several	mice	were	 found	 to	 also	have	 lymphoma	 in	
addition	to	sarcomas	–	these	are	noted	in	the	table.	
Sample	 Age	(mo)	 Sex	 Normal	Type	 Tumor	Type	 Lymphoma	
F8-23	 13.0	 M	 VL	 FS	 Yes	
F1-13	 11.8	 M	 VL	 FS	 No	
F2-3	 9.1	 M	 VL	 FS	 No	
F8-17	 14.2	 M	 VL	 FS	 No	
F3-8	 15.5	 F	 VL	 FS	 No	
F2-4	 16.1	 M	 VL	 FS	 Yes	
F8-70	 10.9	 F	 FR	 OS	 No	
F8-51	 13.4	 F	 FR	 OS	 Yes	
F3-20	 14.3	 F	 FR	 OS	 No	
F7-12	 17.3	 F	 FR	 OS	 Yes	
F3-98	 16.5	 F	 FR	 OS	 No	
F8-49	 13.0	 M	 FR	 OS	 Yes	
F7-2	 19.1	 F	 FR	 OS	 Yes	




(7:1	 female	 to	 male).	 	 We	 have	 no	 reason	 to	 believe	 that	 this	 is	 anything	 more	 than	 a	
statistical	 anomaly,	 but	 may	 be	 worth	 continuing	 to	 monitor	 in	 future	 cohorts.	 	 We	
otherwise	found	no	distinct	trends	for	age	and/or	lymphomas	
7.2 Mouse-specific	variation	necessitates	the	use	of	N/T	pairs	




given	mouse,	 and	 could	 be	 due	 to	 being	 on	 a	 mixed	 background.	 	 These	 patterns	 were	
visible	 grossly,	 at	 the	 chromosome	 level	 when	 looking	 at	 variant	 density	 plots,	 and	 by	 a	
background	check	of	the	mouse.	
When	 generating	mouse	models,	 there	 is	 risk	 for	 introducing	 additional	 variation	
during	the	process,	particularly	when	using	embryonic	stem	cells	(ESC)	for	targeting	(125).	
In	 this	 case,	 especially	 in	 early	 generations,	 the	 flanking	 regions	 around	 the	mutation	 (or	
gene)	often	come	from	the	ESC,	rather	than	the	original	mouse	strain.		This	flanking	region	
can	be	reduced	through	backcrossing,	but	even	after	10	successive	backcrosses,	as	much	as	
1	 cM	 on	 either	 side	 of	 the	 target	 (~40	 genes	 on	 average)	 is	 likely	 to	 retain	 donor	
sequence(125)	(125),	leading	to	the	presence	of	passenger	mutations	around	the	region	of	
interest,	particularly	since	variation	is	generally	called	against	the	background	of	the	original	




























Figure	 43:	 SNP	 data	 checking	 the	 background	 of	 the	 p53	 R172H	 mice	 showing	 that	















For	 fibrosarcomas,	 we	 elected	 to	 use	 the	 vastus	 lateralis	 (VL,	 muscle)	 and	 for	
osteosarcomas	 (OS),	we	used	a	 femur	 (FR,	bone)	as	a	normal	 control.	 	We	expected	 that	









LOH	 (127).	 However,	 in	 our	 pilot	 study,	 in	which	we	 sequenced	 2	 human	 tumors,	 and	 2	
mouse	 tumors	 by	 WGS,	 we	 observed	 one	 tumor	 with	 LOH	 and	 one	 with	 ROH	 for	 each	
organism.	 	 Alerted	 to	 the	 possibility	 that	 LOH	might	 not	 be	 as	 common	 as	 expected,	we	
used	pyrosequencing	 to	quantitatively	determine	 the	extent	of	 LOH	 in	our	mouse	 tumors	







In	 addition	 to	 pyrosequencing	 tumor	 tissues,	 we	 also	 sequenced	 the	 matching	
constitutive	tissues	from	the	same	mouse	as	controls,	finding	two	outliers.		We	found	two	
femurs	that	appeared	to	be	normal	at	gross	observation,	but	had	relatively	advanced	LOH	
by	 pyrosequencing	 (Figure	 45).	 In	 both	 cases,	 LOH	was	more	 pronounced	 in	 the	 tumor,	
relative	to	the	supposedly	normal	femur.	Moreover,	these	femurs	were	not	adjacent	to	the	




Figure	 45:	 Pyrograms	with	 peak	heights.	 	 These	 data	 suggest	 that	we	had	 LOH	 in	what	
appeared	 to	 be	 normal	 femurs	 upon	 gross	 observation.	 	Moreover,	 these	 femurs	were	
distal	 from	 the	 primary	 tumor	 site,	 suggesting	 that	 LOH	 may	 not	 be	 sufficient	 for	
tumorigenesis.	
To	 rule	 out	 the	 possibility	 that	 all	 constitutive	 tissues	 had	 this	 same	 behavior,	 we	













and	 reserve	 the	 other	 for	 experiments,	 such	 DNA	 extractions,	 it	 is	 possible	 that	 the	
sequenced	 femur	 had	 cancerous	 or	 pre-cancerous	 lesions	 that	 were	 not	 visible	 at	 gross	
observation.	 	We	did	not	observe	such	a	pattern	to	be	the	case	for	any	VL/FS	pairs;	no	VL	
samples	had	LOH.	
These	 data	 are	 juxtaposed	 against	 p53-/-	 and	 p53+/-	mice.	 	 In	 p53-/-	 null	 mice,	 the	
penetrance	 of	 tumors	 is	 100%,	 suggesting	 that	 LOH	 alone	 would	 be	 sufficient	 for	
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tumorigenesis.	 	 In	 p53+/-	 mice,	 the	 data	 indicate	 p53	 should	 be	 considered	 to	 be	
haploinsufficient.		Only	half	of	all	tumors	in	mice	under	the	age	of	18	months	had	LOH,	and	
this	 number	 dropped	 to	 just	 15%	 in	 tumors	 over	 18	 months.	 (128)	 However,	 no	 such	






represented	 ROH.	 	 We	 elected	 to	 use	 toe	 tissue,	 originally	 collected	 for	 genotyping,	
between	days	7-10	when	it	is	still	cartilaginous.		Theoretically,	these	tissues	should	have	had	





favor	 the	 A-allele	 is	 unknowable.	 	 Using	 the	 toe	 data	 as	 a	 whole,	 we	 set	 up	 our	 own	
classification	 scheme.	 	 We	 averaged	 the	 allele	 %	 from	 all	 toes,	 and	 then	 calculated	 a	








in	 about	 half	 of	 all	 sarcomas	 (Figure	 47),	 indicating	 the	 LOH	 (at	 the	 R172H	 locus)	 is	 not	
required	for	sarcomagenesis.		These	data	are	also	somewhat	consistent	with	previous	data	
suggesting	that	LOH	is	less	common	in	older	tumors.		Using	an	arbitrary	cutoff	point	of	15	








Figure	 47:	 Depiction	 of	 pyrosequencing	 results	 plotted	 against	 %	 of	 mutant	 and	 WT	
alleles.	 	Mouse	 name,	 tumor	 type	 (fibrosarcoma	 –	 FS,	 osteosarcoma	 –	 OS)	 sex,	 age	 at	
sacrifice,	and	 lymphoma	status	are	 listed	at	 left-hand	column.	 	Data	 indicate	where	 the	
matching	normal	 is	 (always	 femur,	or	vastus	 lateralis	 for	 corresponding	 tumors),	with	a	
solid	line	indicating	the	extent	of	LOH	in	the	tumor.		Additional	dashed	lines	account	for	
tumor	purity	as	indicated	by	the	pathologist	where	available.		The	black,	solid	vertical	line	






















Figure	 48:	 Krahe	 lab	 pipeline	 for	 identification	 of	 somatic	 variation	 in	 WES	 data.	 	 We	
found	somatic	variant	callers	to	produce	widely	disparate	calls	–	to	compensate	for	this,	
we	 looked	 at	 all	 somatic	 variants	 that	 were	 found	 by	 at	 least	 two	 algorithms	 to	 best	
balance	false	positives	and	false	negatives.	
8.1.1 Filtering	for	high-quality	somatic	variants	
In	 our	 pipeline,	 using	 the	 recommended	 best	 practices,	 and	 selecting	 only	 for	
variants	 each	 considered	 to	 be	 high	 confidence,	 we	 saw	 poor	 agreement	 between	 the	
samples	when	looking	at	somatic	SNVs	(Figure	 49).	A	significant	proportion	of	the	 lack	of	





Figure	 49:	 Representative	 Venn	 diagram	 of	 agreement	 between	 five	 different	 somatic	
variant	callers	in	our	mouse	samples.		All	variants	were	called	according	to	best	practices	






positives?	 How	 should	 researchers	 balance	 retaining	 false	 positives,	 with	 true	 positives	
occurring	at	lower	allele	frequencies	(e.g.	arising	by	tissue	heterogeneity).	Consideration	of	
variants	 found	 by	 all	 algorithms	 is	 almost	 certainly	 too	 restrictive	 –	 they	 represent,	 on	
average,	just	0.1%	of	all	somatic	variant	calls	(by	any	algorithm).		In	contrast,	consideration	




by	 exactly	 one	 algorithm,	 by	 exactly	 two	 algorithms	 (any	 pair	 was	 fine),	 by	 any	 three	
algorithms,	and	so	on.		On	average,	about	5%	of	total	somatic	variants	are	called	are	found	
by	3+	algorithms,	and	about	10-15%	of	 total	 somatic	 variants	are	 found	by	2+	algorithms	
(Table	11).	






The	most	 recent	 reported	 overall	 somatic	 mutation	 burden	 for	 human	 adult	 soft	
tissue	sarcomas	is,	on	average,	1.06	per	Mb,	with	the	highest	reported	being	33.5	mutations	
per	 Mb,	 where	 mutations	 are	 considered	 to	 be	 non-synonymous	 SNVs	 (10).	 Back	
referencing	the	data	against	the	cBio	portal	reveals	that	the	samples	with	the	three	highest	
mutation	 loads	 (>350	 total	 mutations)	 have	 somatically	 acquired	 likely	 loss-of-function	
mutations	 in	p53:	 TCGA-DX-AB2E-01	 (R342*,	 age	 53,	myxofibrosarcoma),	 TCGA-3B-A9HT-
01(W91*,	 age	 53,	 leiomyosarcoma),	 and	 TCGA-DX-AB32-01	 (L252del,	 age	 62,	
undifferentiated	 pleomorphic	 sarcoma),	 consistent	 with	 the	 possibility	 that	 p53	 LOF	
alterations	 can	 increase	 mutational	 load.	 	 Four	 patients	 had	 somatic	 mutations	 at	 p53	
R175H,	analogous	to	the	mouse	model;	these	had	36,	59,	62,	and	101	mutations,	at	ages	44,	
73,	64,	and	62	respectively	(10,	22).			
We	 then	 took	 variants	 that	 had	 been	 identified	 by	 two	 or	 more	 algorithms,	 and	
annotated	with	ANNOVAR	 (136),	 SIFT,	 (86)	 and	PROVEAN	 (137)	 to	 further	 select	 for	non-
synonymous	variants	to	see	if	our	mice	were	in	line	with	these	data	(Table	12).	
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Table	12:	Table	 showing	 the	number	of	non-synonymous	SNVs	 found	 in	each	mouse	by	
two	 or	 more	 algorithms	 (2+),	 or	 three	 or	 more	 algorithms	 (3+).	 	 Results	 are	 roughly	

















We	 initially	 looked	 at	 recurrence	 of	 SNVs	 across	 all	 mouse	 tumors,	 finding	 one	
recurrent	 SNV,	 in	 Mroh2a.	 	 This	 variant	 (c.C4088T,	 p.T1363M)	 was	 predicted	 to	 be	
damaging	 (PROVEAN=-4.02,	 threshold	 <	 -2.5;	 SIFT=0.046,	 threshold	 <	 0.05)	 but	 may	 be	
polymorphic;	it	has	an	rsID	but	no	reported	allele	frequencies.		Secondly,	we	looked	to	see	if	












either	 good	 novel	 candidates	 to	 pursue	 further,	 or	 false-positives,	 arising	 perhaps	 out	 of	
multiple	testing	of	the	entire	exome.	
8.2.1.1 Arid1a	
ARID1A	 (in	 humans)	 is	 known	 to	 be	 a	 haploinsufficient	 tumor	 suppressor	 and	 is	 a	
SWI/SNF	 chromatin	 remodeling	 gene	 that	 has	 been	 linked	 to	 several	 cancers,	 including	
ovarian,	gastric,	and	breast	tumors,	but	not	including	sarcomas.		In	fact,	in	one	paper	by	Wu	
et	 al.	 the	 authors	 specifically	 claim	 they	 are	 not	 aware	 of	 any	 ARID1A	 mutations	 being	
detected	in	human	sarcomas	(138).		Moreover,	the	majority	of	cancer-causing	mutations	in	
ARID1A	 that	 have	 so	 far	 been	 identified	 are	 stopgain	 or	 frameshift	 mutations	 (138),	 as	
opposed	 to	 the	 non-synonymous	 SNVs	 we	 identified	 in	 Arid1a	 in	 the	 mouse.	 	 Taken	
together,	these	data	raise	some	doubt	as	to	whether	or	not	these	mutations	could	impact	
sarcomagenesis,	 but	 do	 allow	 that	 ARID1A	 may	 be	 an	 intriguing,	 if	 not	 immediately	
compelling,	candidate	for	follow-up.	
8.2.1.2 Mroh2a	























Disruption	 of	 key	 pathways	 is	 often	 considered	 to	 be	 a	 hallmark	 of	 cancer	 (2,	 54,	
139).		However,	pathways	often	have	built-in	redundancies,	and	a	single	alteration	may	be	
insufficient	for	tumorigenesis	(140).		For	example,	in	renal	carcinoma,	loss	of	VHL	or	PBRM	
alone	 are	 not	 sufficient	 for	 tumorigenesis,	 but	 co-occurring	 VHL,	 PBRM1,	 and	 SETD2	
mutations	are	observed,	the	latter	two	of	which	are	both	involved	in	chromatin	remodeling	
via	the	SWI/SNF	complex	(141,	142).	





hot-spot	mutations	are	 known	 to	be	mutually	exclusive	 from	BRAF	 hot-spot	mutations	at	
codons	600	and	601.	 	That	 is,	each	 is	 strong	enough	on	 its	own	to	 lead	to	 tumorigenesis.		
However,	 some	 hotspot	 NRAS/KRAS/HRAS	 mutations	 have	 been	 shown	 to	 appear	
concomitantly	with	 recurring	mutations	 in	BRAF	 (not	at	 codons	600/601),	 suggesting	 that	
two	 alterations	 in	 the	 same	 pathway	 are	 possible	 or	 even	 required	 (144).	 	 These	
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observations	 indicate	 that	 two	 variants,	 with	 possibly	 weaker	 effects,	 could	 combine	 to	
create	a	similar	effect	as	one	strong	mutation.	
Moreover,	 in	 malignant	 peripheral	 nerve	 sheath	 tumors	 (MPNST),	 a	 soft	 tissue	
sarcoma,	 evidence	 suggests	 that	 activation	 of	 the	 Ras	 pathway	 takes	 multiple	 hits.	 	 In	
addition	to	a	germline	mutation	 in	NF1	 (coupled	with	somatic	 loss),	multiple	MPNSTs	had	
additional	 somatic	 variants,	 predicted	 to	 be	 pathogenic	 (e.g.	 PIK3CA,	 KIT,	 PTPN11,	 and	
FGFR1,	 among	 others)	 (145).	 	 However,	 no	 single	 gene	 has	 emerged	 as	 being	 highly	
recurrent	in	conjunction	with	mutant	NF1.	(145).	 	Taken	together,	these	data	suggest	that	
looking	 for	multiple	 hits	 in	 the	p53	 pathway	 (or	 any	 cancer	 pathway)	 has	 intrinsic	 value,	








	to	 prioritize	 our	 search	 for	 known	 additional	 genetic	 risk	 factors.	 	 These	 lists	 are	 not	
redundant	with	each	other	 (Figure	 51),	with	at	 least	some	of	the	differences	due	to	how	















Given	 previous	 reports	 that	 some	 LFS	 patients	 may	 have	 multiple	 cancer-
predisposing	 mutations	 or	 that	 differing	 p53	 alleles	 have	 different	 penetrance	 (6.3),	 we	
looked	 at	 the	 germline	 mutation	 profiles	 for	 each	 of	 the	 mice	 using	 variants	 called	 by	
HaploCaller.	 	We	 took	 the	 lists	 (146)	 previously	 outlined	 in	 8.2.3	 to	 prioritize	 looking	 for	
known	additional	risk	factors.	
The	majority	of	mice	contain	germline	variants	(non-synonymous,	non-frameshift,	or	









they	may	 be	 haploinsufficient	 (in	 conjunction	with	mutated	p53,	 or	 passengers.	 	 Key	 –	
“0/1”	 indicates	 a	 heterozygous	 variant,	 with	 the	 reference	 allele	 (“0”)	 and	 the	 most	
common	minor	allele	(“1”).		“./.”	indicates	insufficient	data	to	make	a	genotype	call,	often	
due	to	insufficient	coverage.		“0/0”	indicates	a	homozygous	reference/WT	genotype.	




We	 also	 do	 not	 observe	 any	 strong	 predilection	 for	 mice	 in	 our	 cohort	 with	 germline	
variants	 in	Blm	and	Cdk4	 to	develop	osteosarcomas	over	 fibrosarcomas,	suggesting	at	 the	
very	least	they	are	not	driving	the	sarcoma	spectrum	towards	osteosarcomas.	
	 120	
Table	16:	Distribution	of	germline	variants	 in	Blm	and	Cdk4	by	 tumor	 type.	 	Both	genes	
have	 been	 previously	 associated	 with	 osteosarcomas,	 but	 in	 our	 mice,	 show	 no	
predilection	towards	OS	over	FS.	
	
Moreover,	 it	 is	 not	 known	 if	 these	 variants	may	 be	 polymorphisms	 (though	 they	 do	 not	
carry	dbSNP	IDs).	
We	 also	 examined	 our	mouse	 cohort	 for	 non-recurrent	 variation,	 looking	 at	 each	
mouse	individually	for	mutations	in	key	genes.		Three	mice	from	our	cohort	have	germline	
variants	 in	 sarcoma	 predisposition	 genes,	 and	 LOH	 in	 the	 tumor.	 	 RsH-F7-2	 (OS)	 has	 a	
nonsynonymous	SNV	in	Chek2	that	is	predicted	to	be	damaging	(p.G263C,	SIFT=0.04).		Both	
RsH-F7-12	 (OS)	 and	RsH-F8-70	 (OS)	 have	 the	 same	germline	mutation	 in	Bub1b,	 (p.L726I,	
SIFT=0.033),	 a	 gene	 associated	 with	 embryonal	 rhabdomyosarcoma	 and	 aneuploidy	 in	
humans	 (147),	 and	 LOH	 in	 the	 tumor.	 	 Interestingly,	 in	 humans,	 both	CHEK2	 and	BUB1B	
have	been	associated	with	chromosomal	 instability	(147-150).	 	Although	alterations	 in	the	
two	 genes	 are	 not	 considered	 sufficient	 for	 chromosomal	 instability	 (CIN)	 on	 their	 own	
(151),	these	mice	all	have	the	germline	mutation	in	p53	(and	LOH	in	the	tumor).	Thus,	it	is	
probable	that	some	germline	variants	in	these	genes	contributed	to	tumorigenesis	in	these	
mice,	 especially	 given	 their	 LOH	 in	 the	 tumors.	 	 While	 an	 accurate	 estimation	 of	 the	
penetrance	 of	 these	 germline	mutations	 in	 the	 context	 of	 an	 underlying	p53	mutation	 is	





Unfortunately,	 RNA	 extractions	 from	 fresh	 frozen	 tissues	 in	 the	 mouse	 produced	





























Figure	 54:	 PCA	 analysis	with	 the	 pyrosequencing	 LOH	 data	 laid	 over	 the	 top.	 	 There	 is	
















































































DNA,	 we	 looked	 at	 either	 at	 WGS,	 or	 at	 WES	 in	 conjunction	 with	 low-coverage	 WGS	
(lcWGS).	 	 The	 majority	 of	 the	 normal/tumor	 pairs	 were	 assayed	 on	 Illumina	 at	 40X/80X	
coverage	 respectively.	 	 One	 sample	 was	 assayed	 on	 the	 Complete	 Genomics	 platform	
(STS170-038).	Analysis	 for	 Illumina	samples	was	done	with	the	pipeline	outlined	 in	Figure	48.	
For	RNA,	we	were	unable	to	isolate	high-quality	RNA	from	fresh	tissues,	presumably	
due	 to	handling	at	 the	 time	of	 tumor	extraction	 (and	understandable	prioritization	of	 the	
patient),	 but	we	were	able	 to	 leverage	FFPE	 tissues	 instead	 to	acquire	 suitable	RNA.	 	 For	
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methylation	 data,	 we	 used	 the	 EPIC	 array	 (Illumina),	 and	 analyzed	 the	 data	 via	 the	 R-
package	minfi	 (156).	 	 Although	we	 still	 considered	 recurrence	 as	 an	 endpoint,	 analysis	 of	
both	RNA	and	methylation	data	is	further	complicated	by	sample	availability.		For	example,	
for	osteosarcomas,	we	would	ideally	sequence	a	tissue-matched	normal	bone,	rather	than	
the	muscle,	due	 to	 tissue	 specificity	 in	RNA	and	methylation.	 	We	can	get	around	 this	by	
sequencing	more	appropriate	 tissue	 controls	 (e.g.	 a	normal	osteoblast	 cell	 line),	but	 then	
these	normal	cell	line	controls	lack	the	underlying	p53	mutations	present	in	the	constitutive	
tissue.		Moreover,	recurrence	analysis	is	potentially	confounded	by	the	variety	of	underling	










Initial	 analysis	 of	 the	 human	 tumors	 for	 recurrent	 somatic	 changes	 in	 the	DNA	 found	 no	
overlap,	either	at	the	mutation	or	gene	level,	with	the	exception	of	p53.				
The	 lack	of	overlap	could	arise	out	of	 several	 scenarios.	 	First,	given	 the	variety	of	
germline	mutations	and	tumor	types,	these	tumors	may	have	distinct	etiologies	from	each	
other.	 	 Secondly,	 tumor	 heterogeneity,	 clonality,	 and	 contamination	 from	 normal	 tissue	
may	obfuscate	variant	calling.	 	 Such	mutations,	occurring	 in	 just	a	 fraction	of	 the	sample,	
could	be	missed	without	using	deep	sequencing.	 	Thirdly,	 tumorigenesis	 in	 these	patients	
may	be	driven	by	something	other	than	somatically	acquired	SNVs	or	indels,	such	as	CNAs	
or	epigenetic	changes.	
Therefore,	 to	work	around	the	 fact	 that	 these	potentially	confounding	variables	as	
best	 as	 possible,	 we	 examined	 each	 of	 the	 tumors	 individually	 for	 both	 germline	 and	
somatic	variants.			
9.2 Some	human	tumors	had	additional	germline	variants	in	cancer	genes	
Analysis	 of	 germline	 variation	 did	 find	 two	 individuals	 with	 rare	mutations	 in	 key	
cancer-related	 genes.	 	 MGC900-001	 (p53	 R273H,	 breast	 cancer)	 had	 a	 mutation	 in	 the	
breast	cancer	predisposition	gene	CHEK2	(p.R180C,	MAF	<0.01%)	that	was	predicted	to	be	
damaging	 (SIFT=0.18,	 PP2=1).	 	 Notably,	 CHEK2	 had	 previously	 been	 associated	 with	 LFS	
(2.3.1).		A	second,	different	individual	(SMN119-000,	p53	del	ex	1-9)	had	a	mutation	in	the	








also	at	 the	somatic	 level.	 	 Individual	 sarcomas	had	notable	 somatic	mutations	 in	 sarcoma	
related	genes.		One	tumor	had	an	early,	heterozygous,	somatic	stop-gain	mutation	in	PTEN	
(p.G20X).		Given	that	PTEN	is	a	haploinsufficient	TSG	(157,	158),	such	a	mutation	would	be	
expected	 to	have	 functional	 consequences.	 	A	 second	 tumor	had	a	 stop-gain	mutation	 in	
NOTCH1.	 	 NOTCH1	 is	 a	 transmembrane	 receptor	 that	 is	 typically	 considered	 to	 be	 an	
oncogene,	 having	 been	 found	 to	 be	 up-regulated	 in	 synovial	 sarcomas	 and	




role	 in	 tumor	 maintenance	 (159).	 	 Indeed,	 the	 role	 of	 Notch	 signaling	 is	 becoming	
considerably	more	complex	than	initially	suspected.		For	example,	NOTCH1	has	been	shown	
to	be	activated	in	some	osteosarcomas	(160),	but	in	other	cases,	it	has	also	been	shown	to	
have	 tumor	 suppressive	 properties	 (161),	 suggesting	 a	 highly	 context-dependent	 role	 for	
Notch	signaling	that	may	be	either	oncogenic	or	tumor-suppressive	(161).	
Overall,	 the	 lack	 of	 consensus	 in	 the	 human	 samples,	 possibly	 due	 to	 tumor	 type	
heterogeneity,	may	argue	for	a	different	approach.		Rather	than	use	the	human	samples	as	





Alternatively,	other	 types	of	 alterations	may	explain	 the	 lack	of	 consensus	 seen	 in	
somatic	mutations.		Chromosomal	instability	is	considered	to	be	hallmark	of	sarcomas	(10).		
We	 worked	 with	 Dr.	 Nicholas	 Navin	 and	 a	 graduate	 student	 of	 his,	 Naveen	 Ramesh,	 to	
generate	 copy	 number	 analyses	 using	 our	 WES	 and	 lcWGS	 data	 and	 their	 pipeline.		
Consistent	with	previously	published	data,	we	observed	copy	number	alterations,	especially	
across	our	tumors	with	point	mutations	in	p53	(Figure	57).		Our	data	is	generally	consistent	
with	 reported	 data	 for	 sarcomas	 in	 that	 deletions	 are	more	 common	 than	 amplifications	
(10).		Both	MGC900-001	and	SMN669-000	tend	to	have	more	deletions	than	amplifications,	










significant	 copy	 number	 aberrations	 in	 human	 LFS	 tumors.	 	 Data	 generated	 in	
collaboration	with	Naveen	Ramesh	(Dr.	Nicholas	Navin	lab).	 	Grey	lines	represent	ploidy	




Figure	 58:	 Copy	 number	 analysis	 of	 human	 tumors	 with	 deletions	 in	 p53	 indicates	
relatively	 few	copy	number	aberrations	 in	 some	human	LFS	 tumors.	 	Data	generated	 in	
collaboration	with	Naveen	Ramesh	(Dr.	Nicholas	Navin	lab).	 	Grey	lines	represent	ploidy	





For	 human	 methylation	 data,	 we	 used	 Illumina’s	 HumanMethylationEPIC	 (EPIC)	
array	 on	 the	 same	 DNA	 that	 we	 used	 to	 perform	 WES	 and	 lcWGS.	 	 To	 analyze	 human	
methylation	 data,	 we	 used	 the	minfi	 R-package	 and	 ssnoob	 pre-processing,	 followed	 by	
bumphunter	 to	 find	differentially	methylated	 regions	 (DMRs)	as	described	by	Fortin	et	 al.	
(162).	
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The	method	calls	 for	a	minimum	default	 cutoff	of	0.2	 (i.e.	a	20%	difference	 in	 the	
beta-values	 between	 normal/tumor),	 but	 for	 some	 samples	 this	 led	 to	 hundreds	 of	
thousands	of	candidate	bumps	and	long	compute	times.		Since	past	a	certain	point,	results	
are	 less	 likely	 to	 be	 considered	 significant	 after	 adjusting	 for	 multiple	 testing	 and	
permutations,	the	general	consensus	is	to	increase	the	cutoff	(in	our	case	up	to	about	a	50%	
difference	 in	 beta	 values),	 in	 order	 to	 drive	 the	 number	 of	 candidate	 bumps	 (without	
consideration	of	p-value)	down	to	~30,000-40,000.	 	We	can	see	then	some	normal/tumor	
pairs	 have	 very	 few	 DMRs	 (SMN1119-000,	 and	 STS170-000),	 while	 others	 must	 have	





























al.	 demonstrated	 that	 knock	 down	 of	 JARID2	 inhibited	 invasiveness	while	 overexpression	





















different	p53	 alleles	 have	 different	 penetrances,	 and	 considering	 that	 different	 sarcomas	
may	 have	 different	 etiologies	 (10,	 15,	 172),	 this	 may	 not	 be	 too	 surprising.	 	 An	 overall	








stable.	 	 For	 rare	 diseases/tumors	 such	 as	 LFS/sarcomas,	 the	 reduction	 of	 confounding	
factors	 (e.g.	 genetic	 heterogeneity)	 can	 be	 a	 powerful	 discovery	 space.	 	 For	 example,	
MIR219A2	 is	 recurrently	 hypermethylated	 in	 all	 mouse	 tumors,	 which	 we	 then	 found	 to	
have	a	deep	deletion	in	sporadic	MPNSTs.			
In	 contrast,	 many	 tumors	 across	 mice	 and	 human	 showed	 alterations	 at	 the	
germline,	somatic	or	methylation	level	in	well–known	sarcoma	genes	like	PTEN.		If	these	are	
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sufficient	 on	 their	 own	 to	 lead	 to	 sarcomagenesis,	 it	 reduces	 the	 value	 in	 looking	 for	
recurrence	 in	 trying	 to	 identify	novel	 cancer	 genes.	 	However,	 this	 does	not	mean	 that	 a	
comparative	approach	 is	without	merit.	 	The	Cancer	Gene	Census	currently	 identifies	610	
genes	 (https://cancer.sanger.ac.uk/census),	 and	 represents	 a	 good	 baseline	 for	 the	 low-
hanging	fruit.		However,	it	is	important	to	note	that	there	likely	are	additional	undiscovered	
cancer	genes	 that	can	be	 found,	particularly	using	a	case	study	approach.	 	 Increasingly,	 it	
appears	that	cancer	subtypes	may	have	distinct	etiologies,	including	in	sarcomas	(10,	15).			
Additionally,	 one	 way	 to	 further	 identify	 novel	 cancer	 genes	 may	 be	 to	 look	 for	
genes	 that	 cooperate	 with	 known	 players	 such	 as	 p53.	 	 Previously,	 we	 discussed	 the	
possibility	 that	while	 disruption	 of	 key	 pathways	 is	 often	 considered	 to	 be	 a	 hallmark	 of	
cancer	(2,	54,	139),	pathways	often	have	built-in	redundancies,	and	a	single	alteration	may	




obscures	 these	 data,	 or	 that	 considering	 multiple	 alterations	 may	 have	 more	 predictive	
power.		
Overall,	our	data	agrees	with	previously	published	data	–	sarcomas	have	relatively	
low	 point	mutation	 burdens,	 but	many	 have	 significant	 copy	 number	 aberrations	 (CNAs)	
(10,	15).	 	 Intriguingly,	 in	our	data,	patients	with	germline	point	mutations	 in	p53,	 tend	 to	








moving	 forward,	 requiring	 expertise	 across	 a	 variety	 of	 fields,	 ranging	 from	 accurate	








model	 for	 even	 rarer	 types	 may	 not	 be	 possible.	 	 Alternatively,	 given	 sufficient	 time	
clinicians	 may	 collect	 enough	 samples	 from	 human	 patients	 to	 complete	 such	 a	 study.		
Importantly	though,	we	have	used	our	data	to	 identify	potential	 impact	players	which	are	
both	 novel	 (e.g.	 MIR219A2,	 and	 with	 known	 roles	 in	 other	 cancers	 such	 as	 PTEN	 and	
BUB1B).	 	 Some	 of	 these	 have	 appeared	 to	 be	 common	 to	 both	 osteosarcomas	 and	
fibrosarcomas,	 suggesting	 the	 potential	 that	 some	 drivers	 may	 be	 common	 to	 multiple	
sarcomas.	 	 Thus,	 a	 comparative	 omics	 approach	 gives	 tremendous	 value	 to	 focusing	 on	




Secondly,	 our	 data	 indicate	 that	 genetic	mutations	 even	 in	 known	 sarcoma	 genes	
such	 as	PTEN	 are	 generally	 rare	 across	 our	 samples,	 underlying	 an	 important	 point	 –	 the	
majority	 of	 sarcomas	 have	 low	 point	mutation	 loads	 and	 instead	 are	 considered	 to	 have	
significant	 copy	 number	 aberrations	 (10).	 	 In	 addition,	 some	 sarcoma	 subtypes,	 such	 as	
synovial	 sarcoma	 subtypes	 had	 relatively	 uniform	methylation	 profiles	 (10).	 	We	 noticed	
consistent	 patterns	 in	 our	 mouse	 methylation	 data,	 including	 some	 genes	 that	 were	
recurrently	 hypermethylated	 and	 a	 PCA	 analysis	 that	 grouped	 both	 osteosarcomas	 and	
fibrosarcomas	together.	 	Moreover	several	of	 the	top	hits	 in	 the	human	methylation	data	
had	known	functions	in	cancers.		We	highlighted	four	oncogenes	that	were	hypomethylated	
(e.g.,	 PTPRN2,	 JARID2),	 and	 two	 tumor	 suppressor	 genes	 were	 hypermethylated	 (e.g.,	







segregates	with	 disease	 across	multiple	 LFSL	 families	 (four	 total	 to	 date).	 	Moreover,	we	
have	demonstrated	that	this	mutation,	ARGAHP30	(c.G161,017,761A,	p.R806Q/p.R1017Q),	
has	 functional	 impact	when	 overexpressed	 in	 vitro	 for	 both	 the	 short	 and	 long	 isoforms,	
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suggesting	that	ARHGAP30	may	have	p53-independent	functions.		To	further	strengthen	our	
case,	 we	 are	 currently	 sequencing	 additional	 LFSL	 families	 to	 see	 if	 they	 contain	 other	
mutations	 in	 elsewhere	 in	ARHGAP30,	 and	 testing	 tumors	 to	 see	 if	 they	have	 LOH.	 	 Both	
results	 substantially	 strengthen	 the	 identification	 of	 ARHGAP30	 as	 an	 LFSL	 gene	 and	 an	
important	gene	for	clinical	testing	for	patients	and	families	with	LFS/LFSL	phenotypes.		Our	
hope	 and	 intention	 is	 that	 this	 will	 allow	 for	 genetic	 testing	 and	 improved	 tumor	
surveillance	in	individuals	who	have	this	genetic	germline	cancer	predisposition.		
Secondly,	 we	 have	 demonstrated	 the	 utility	 of	 a	 comparative	 –omics	 approach	 to	
identify	 potential	 key	 players	 in	 sarcomagenesis.	 	 Recent	 research	 by	 TCGA	 emphasizes	
tissue	 specificity	 in	 adult	 soft	 tissue	 sarcomas	 (10),	 and	 suggests	 significant	 value	 in	
sequencing	 similar	 sarcoma	 types.	 	We	 were	 able	 to	 leverage	 a	 mouse	model	 of	 LFS	 to	
identify	 two	novel	genes,	Mroh2a,	 and	Mir219a-2	as	potential	players	 in	 sarcomagenesis,	
the	 latter	 of	which	 has	 relevance	 to	MPNSTs	 (145).	 	 Strikingly,	 although	we	 observe	 few	
overlaps	in	somatic	mutations	(at	the	base	or	gene	level),	we	do	observe	significant	overlap	




However,	 our	 data	 also	 indicate	 that	 all	 types	 of	 -omics	 approaches	 can	 point	 to	
alterations	 in	key	genes,	and	 that	 these	may	be	 relatively	private.	 	 In	 combination	with	a	
large	 existing	 knowledge	 base	 in	 cancer,	 these	 “private”	 alterations	 may	 be	 considered	
generally	sufficient	to	explain	tumorigenesis.		We	note	that	it	is	possible	that	these	tumors	
	 145	
have	 other	 mutations	 that	 contribute	 to	 cancer	 in	 smaller	 ways,	 or	 may	 be	 involved	 in	




In	 conclusion,	 based	 on	 our	 collective	 data	we	would	 argue	 that	 to	 best	 understand	
sarcomagenesis	moving	 forward,	one	 should	 focus	on	 complete	 tumor	profiling	 in	 as	 few	
subtypes	as	possible.		Furthermore,	we	would	recommend	an	emphasis	on	evaluating	CNAs	
and	methylation	profiles,	ultimately	 suggesting	 there	 is	 still	 strong	utility	 in	using	LFS	and	
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